<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        48-212-96
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1996
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FELDENE 20MG-ML AMP.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIROXICAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M02AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: NON-STEROIDAL ANTI-INFLAMMATORIES &ndash; ATC code: M01AC01.</p><p>Before prescribing you piroxicam, your doctor must evaluate the benefits that this medicine could have for you compared to the risk of developing side effects. Your doctor will only prescribe you piroxicam if your symptoms are not sufficiently relieved with other non-steroidal anti-inflammatories (NSAIDs).</p><p>FELDENE 20 mg/ mL solution for injection in ampoules is used as short-term treatment to relieve certain symptoms during episodes of rheumatoid arthritis and ankylosing spondyloarthritis (rheumatic conditions of the spine), such as swelling, stiffness and joint pain. This medicine is used by injection when the oral and rectal routes cannot be used.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Never take FELDENE 20 mg/mL, solution for injection (IM) </strong></p><p>&bull; if you are allergic to the active substance or to any of the other ingredients of this medicine, listed in section 6,</p><p>&bull; if you are pregnant, from the start of the 6th month of pregnancy (beyond 24 weeks of amenorrhoea),</p><p>&bull; history of allergy or asthma triggered by taking this medicine or another similar medicine, particularly other non-steroidal anti-inflammatories, aspirin,</p><p>&bull; history of severe skin reactions such as exfoliative dermatitis (intense reddening of the skin with peeling of the skin in scales or layers), vesiculobullous reactions (Stevens-Johnson syndrome, a condition where the skin is bloody with red blisters, erosion and scabs) and Lyell&rsquo;s syndrome (serious skin condition characterised by blisters and the detachment of the upper layer of the skin),</p><p>&bull; history of ulcers, bleeding or perforation of the stomach or intestines,</p><p>&bull; current or past digestive disorders (inflammation of the stomach or intestines) that predispose you to bleeding disorders such as haemorrhagic rectocolitis, Crohn&#39;s disease, gastrointestinal cancers or diverticulitis (inflammation or infection of the vesicles of the colon),</p><p>&bull; intake of acitretin,</p><p>&bull; active duodenal or stomach ulcer,</p><p>&bull; serious heart disease,</p><p>&bull; serious liver disease,</p><p>&bull; serious kidney disease,</p><p>&bull; children under 15 years of age,</p><p>&bull; aorto-coronary bypass (cardiac surgery to bypass a constricted artery),</p><p>&bull; in premature infants and full-term newborns, as this medicine contains benzyl alcohol and propylene glycol (see &ldquo;Warnings and precautions&rdquo;),</p><p>&bull; intake of mifamurtide.</p><p>If any of the situations above applies to you, you should not take piroxicam.</p><p>Inform you doctor immediately if any of these situations applies to you.</p><p>IF YOU ARE UNSURE OF ANYTHING, IT IS ESSENTIAL THAT YOU ASK YOUR DOCTOR OR PHARMACIST FOR ADVICE</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking FELDENE 20 mg/mL, solution for injection in ampoule (IM).</p><p><strong><u>Warnings</u></strong></p><p>THIS MEDICINE SHOULD ONLY BE TAKEN UNDER MEDICAL SUPERVISION.</p><p>Be careful with FELDENE 20 mg/mL, solution for injection in ampoule (IM) and make sure you always inform your doctor before using it. As with all non-steroidal anti-inflammatories (NSAIDs), FELDENE 20 mg/mL, solution for injection (IM) can cause serious gastrointestinal reactions, such as pain, bleeding, ulcer or perforation. The administration of doses greater than 20 mg per day increases the risk of gastrointestinal side effects.</p><p>Medicines such as FELDENE 20 mg/mL, solution for injection (IM) could increase the risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke. The risk increases when the doses used are higher and the duration of treatment longer. Do not exceed the recommended doses nor the treatment duration.</p><p>If you have heart problems, if you have had a stroke or if you think you have risk factors for this type of disease (for example, if you have high blood pressure, diabetes, high cholesterol levels or if you are a smoker), inform you doctor or pharmacist.</p><p>INFORM YOUR DOCTOR:</p><p>&bull; if you have a history of asthma associated with chronic rhinitis, chronic sinusitis or polyps in the nose.</p><p>Administration of this medicine can cause an asthma attack, particularly in certain patients who are allergic to aspirin or a non-steroidal anti-inflammatory (see section &ldquo;Never take FELDENE 20 mg/mL, solution for injection in (IM)&rdquo;),</p><p>STOP TREATMENT IMMEDIATELY AND INFORM YOUR DOCTOR if you have:</p><p>&bull; stomach pain, or any sign of gastrointestinal bleeding (blood coming up to the mouth, presence of blood in the stool or black coloured stool),</p><p>&bull; allergic reaction as seen by a skin eruption, swelling of the face, wheezing or difficulty breathing,</p><p>&bull; in the event of abnormalities or an aggravation of liver function.</p><p>&bull; if you develop a rash or skin symptoms, you should stop taking FELDENE 20 mg/mL, solution for injection (IM) immediately, seek prompt medical advice and tell your doctor that you are taking this medicine</p><p><strong><u>Precautions</u></strong></p><p>This medicine is available in other dosage forms that can be more suitable. It is important to inform the doctor preparing your prescription if you have any of the following, as this will require dose adjustment:</p><p>&bull; if you have a history of digestive events (digestive bleeding, hiatal hernia, history of stomach or duodenal ulcer),</p><p>&bull; if you have heart, liver or kidney disease</p><p>If you are over 70 years of age, your doctor may need to reduce the treatment duration and see you more frequently during the period of piroxicam administration.</p><p>If you are over 70 years of age or if you are taking medicines such as corticosteroids or other medicines against depression called selective serotonin reuptake inhibitors (SSRIs) or acetylsalicylic acid to prevent the formation of blood clots, or if you consume alcohol, your doctor may prescribe you a medicine to protect your gastric mucosa at the same time as FELDENE 20 mg/mL solution for injection in ampoule (IM).</p><p>You must not take this medicine if you are over 80 years of age.</p><p>If you have current or past medical problems or allergies, or if you are not sure if you should use piroxicam, please inform your doctor before using this medicine.</p><p>Make sure that you have told your doctor all the other medicines that you may be taking, including those that you purchased without a prescription.</p><p>IF YOU ARE UNSURE OF ANYTHING, DO NOT HESITATE TO ASK YOUR DOCTOR OR PHARMACIST FOR ADVICE</p><p><strong>Children and adolescents</strong></p><p>Not applicable.</p><p><strong>Other medicines and FELDENE 20 mg/ ml solution for injection (IM)</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Please inform your doctor of the other medicines that you are taking or have recently taken (during the last week), including medicines that you purchased yourself without a prescription.</p><p>Some medicines can sometimes interfere with the activity of other medicines. Your doctor may limit your use of piroxicam or other medicines or give you a different medicine. It is particularly important to inform him or her:</p><p>&bull; if you are taking mifamurtide,</p><p>&bull; if you are taking acitretin,</p><p>&bull; if you are taking acetylsalicylic acid or another non-steroidal anti-inflammatory for pain relief,</p><p>&bull; if you are taking oral corticosteroids, which are medicines that are given to treat various conditions such as allergies and hormonal imbalances,</p><p>&bull; if you are taking anticoagulants such as coumarin-type derivatives (warfarin) and direct oral anticoagulants (for example apixaban, dabigatran, rivaroxaban) to prevent blood clots from forming,</p><p>&bull; if you are taking certain medicines intended to treat depression called selective serotonin reuptake inhibitors (SSRIs), lithium,</p><p>&bull; if you are taking medicines such as acetylsalicylic acid to prevent platelet aggregation,</p><p>&bull; if you are taking methotrexate,</p><p>&bull; if you are taking heparins, &bull; if you are taking other potassium-sparing agents,</p><p>&bull; if you are taking pemetrexed (used to treat lung cancer),</p><p>&bull; if you are taking cyclosporin, tacrolimus (used to decrease the body&rsquo;s defences in the case of transplants or certain skin diseases),</p><p>&bull; if you are taking medicines for hypertension,</p><p>&bull; if you are taking diuretics,</p><p>&bull; if you are taking deferasirox,</p><p>&bull; if you are taking tenofovir disoproxil,</p><p>&bull; if you are taking nicotinic acid,</p><p>&bull; if you are taking medicines causing a withdrawal reaction,</p><p>&bull; if you are taking vitamin K antagonists,</p><p>&bull; if you are taking irreversible MAOIs,</p><p>&bull; if you are taking insulin,</p><p>&bull; if you are taking sedatives,</p><p>&bull; if you are taking metformin</p><p>&bull; if you are taking hypoglycaemic sulfamides,</p><p>&bull; if you are taking platelet anti-aggregants,</p><p>&bull; if you are taking cobimetinib,</p><p>&bull; if you are taking mixed adrenergic-serotonergic drugs,</p><p>&bull; if you are taking nicorandil.</p><p><strong>FELDENE 20 mg/ml, solution for injection (IM) with food and drink</strong></p><p>Not applicable.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.</strong></p><p><strong><u>Pregnancy</u></strong></p><p><strong>Before the beginning of the 6<sup>th</sup> month of pregnancy </strong>(up to the 24<sup>th</sup> week of amenorrhoea),</p><p>you should not take this medication except in case of absolute necessity determined by your doctor, due to the potential risk of miscarriages or deformities. In this case, the dose should be as low as possible and the duration of treatment as short as possible.The health care professionals should consider ultrasound monitoring of amniotic fluid if NSAID treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found.</p><p><strong>After 12 weeks without menstruation</strong>, this medicine can cause kidney problems in your baby, if taken for several days, which can lead to a low level of the amniotic fluid surrounding the baby (oligoamnios). Narrowing of the blood vessels (constriction of the arterial canal) in your baby&rsquo;s heart may occur after 20 weeks without menstruation. If several days of treatment are needed, your doctor may recommend additional monitoring.</p><p><strong>From the start of the 6<sup>th</sup> month until the end of pregnancy </strong>(beyond 24<sup>th</sup> week of amenorrhoea), this medicine is <strong>contraindicated</strong>, which means that you<strong> MUST NOT </strong>take this medicine, because the effects on your baby, especially on his/her heart, lungs and/or kidneys, can be serious or even fatal, even with a single dose.</p><p>Benzyl alcohol may cross the placental barrier (see below).</p><p>If you have taken this medicine while pregnant, talk to your obstetrician-gynaecologist immediately, to make sure that you are offered suitable monitoring if necessary.</p><p><strong><u>Breast-feeding</u></strong></p><p>As this medicine passes into breast milk, it is not recommended to use it while breast-feeding.</p><p><strong><u>Fertility</u></strong></p><p>Like all non-steroidal anti-inflammatories (NSAIDs), this medicinal product can alter fertility in women and cause difficulties in becoming pregnant, being reversible when the treatment is discontinued. Tell your doctor if you are planning to become pregnant or having difficulties conceiving.</p><p><strong>Driving vehicles and using machines</strong></p><p>In rare cases, use of this medicine can cause dizziness and drowsiness.</p><p><strong>FELDENE 20 mg/ml solution for injection (IM) contains benzyl alcohol, ethanol, propylene glycol and sodium.</strong></p><p><em>This medicine contains 20 mg of benzyl alcohol per ampoule.</em></p><p>Benzyl alcohol can lead to allergic reactions.</p><p>Benzyl alcohol, a preservative, is associated with a risk of serious adverse events, including breathing problems (called &ldquo;gasping syndrome&rdquo;) and death in young children. While at the usual therapeutic doses, the quantities of benzyl alcohol delivered are considerably less than doses at the origin of &ldquo;gasping syndrome&rdquo;, the minimum quantity of benzyl alcohol for which toxicity may occur is not known.</p><p>Premature infants and infants with a low birth weight have a greater risk of presenting with toxicity. It may also cause toxic reactions and allergic reactions in infants and children up to 3 years old (see &ldquo;Never use FELDENE 20 mg/ ml, solution for injection in vial (IM) in following cases&rdquo;).</p><p>Inform your doctor or pharmacist if you are pregnant or if you are breast-feeding. Large quantities of benzyl alcohol can accumulate in your body and cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>Inform your doctor or pharmacist if you have a liver or kidney disease. Large quantities of benzyl alcohol can accumulate in your body and cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><table border="1" cellspacing="1" cellpadding="1" style="width:943px"><tbody><tr><td style="width:939px"><p>WARNING THE ALCOHOL CONTENT OF THE SOLUTION IS 12.6% (V/V) OR 100 mg OF ALCOHOL PER AMPOULE.</p></td></tr></tbody></table><p><em>This medicine contains 12.6% volume of ethanol (alcohol), i.e. 100 mg per ampoule, which is the equivalent of 2.47 mL of beer or 1.03 mL of wine per ampoule.</em></p><p>The use of this medicine is dangerous in alcoholic subjects and should be taken into consideration in women who are pregnant or breast-feeding, children and high-risk groups, such as those with hepatic insufficiency or epilepsy.</p><p><em>This medicine contains 400 mg of propylene glycol per ampoule and may cause similar symptoms to those caused by alcohol</em>.</p><p>If you are pregnant or breastfeeding, do not use this medicine except on your doctor&#39;s advice. Your doctor might proceed to additional examinations while you are taking this medicine.</p><p>If you have a liver or kidney disease, use this medicine only if advised by your doctor. Your doctor might proceed to complementary examinations while you are taking this medicine.</p><p><em>This medicine contains less than 1 mmol sodium (23 mg) per ampoule, that is to say essentially &quot;sodium-free&rdquo;</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong><u>Posology</u></strong></p><p><strong>Adults and elderly patients:</strong></p><p>The maximum daily dose is 20 milligrams (1 ampoule) of piroxicam in a single daily dose. Your doctor may prescribe you another medicine intended to protect your stomach and intestines against possible side effects in combination with piroxicam.</p><p>IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR&rsquo;S PRESCRIPTION.</p><p><strong><u>Method of administration</u></strong></p><p>Intramuscular route.</p><p>This medicine can be injected either with a glass syringe or with a single-use syringe. Inject the medicine as soon as you fill up the syringe. The injections must be administered deeply and slowly under strictly aseptic conditions in the upperouter quadrant of the buttock. If repeated injections are given, change sides for each injection. It is important to pull back slightly on the plunger before injecting the medicinal product to make sure that the tip of the needle is not in a blood vessel. If the injection is very painful, stop the injection immediately. If you have a hip prosthesis, administer the injection contralaterally.</p><p><strong><u>Frequency of administration</u></strong></p><p>One single injection per day.</p><p>IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR&rsquo;S INSTRUCTIONS.</p><p><strong><u>Duration of treatment</u></strong></p><p>It is on the order of 2 or 3 days. Beyond that, continue oral or rectal treatment. IN ALL CASES, STRICTLY FOLLOW YOUR DOCTOR&rsquo;S INSTRUCTIONS.</p><p><strong>If you have used more FELDENE 20 mg/mL, solution for injection (IM) than you should have</strong> Immediately consult your doctor or pharmacist.</p><p><strong>If you forget to use FELDENE 20 mg/mL, solution for injection (IM)</strong></p><p>Not applicable.</p><p><strong>If you stop using FELDENE 20 mg/mL, solution for injection (IM) </strong></p><p>Not applicable.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, but not everyone gets them.</p><p>Medicines such as FELDENE 20 mg/ ml solution for injection could increase the risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke.</p><p>The following may occur:</p><p><strong>Common adverse effects (may affect up to 1 in 10 people):</strong></p><p><em><u>Effects on the metabolism and nutrition</u>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (anorexia).</p><p><em><u>Effects on the nervous system:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, dizziness, drowsiness, vertigo.</p><p><em><u>Effects on the ear:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; buzzing in the ears.</p><p><em><u>Digestive effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heavy feeling in the abdomen, nausea, constipation, abdominal discomfort, flatulence, abdominal pain, diarrhoea, vomiting, indigestion.</p><p><em><u>Effects on the skin:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, itching (pruritus).</p><p><em><u>General effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of certain parts of the body due to liquid infiltrating into the tissues (oedema, particularly of the legs).</p><p><em><u>Effects on the biological test:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible elevations of blood urea nitrogen, transitory or reversible increased serum transaminase levels (enzymes found inside cells),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in hemoglobin (a protein in red blood cells that carries oxygen to the tissues and gives blood its red color) and hematocrit (percentage of the volume occupied by red blood cells compared to the total blood volume) unassociated with obvious gastro-intestinal bleeding.</p><p><u>If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping</u> <u>treatment.</u></p><p><strong>Uncommon adverse effects (may affect up to 1 in 100 people):</strong></p><p><em><u>Effects on the eye:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision.</p><p><em><u>Cardiac effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; perception of heartbeats (palpitations).</p><p><em><u>Digestive effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation in the mouth (stomatitis).</p><p><em><u>Effects on the biological test:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reversible elevations of creatinine in the blood (may be a sign of a kidney problem).</p><p><u>If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping</u> <u>treatment.</u></p><p><strong>Adverse effects with not known frequency (frequency cannot be estimated from the available data):</strong></p><p><em><u>Effects on the blood:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally low levels of certain cells in the blood which may result in paleness or intense fatigue (red blood cells), signs of infection or unexplained fever (white blood cells), bleeding from the nose or gums (platelets) or abnormally high levels of other cells in the blood (eosinophils).</p><p><em><u>Effects on the immune system:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (anaphylactic reactions),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions related to the appearance of antibodies (serum sickness).</p><p><em><u>Effects on the metabolism and nutrition:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally high blood glucose levels (hyperglycaemia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal decrease in blood glucose levels (hypoglycaemia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid retention, sodium retention,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of potassium in the blood (hyperkalemia).</p><p><em><u>Effects on the nervous system:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neck stiffness with fever and sometimes coma (aseptic meningitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity disorder that includes stinging, numbness and tingling in a limb, usually in the extremities (paresthesia).</p><p><em><u>Effects on the eye:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye irritation, swollen eyes.</p><p><em><u>Effects on the ear:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased hearing.</p><p><em><u>Vascular effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute inflammation of the walls of blood vessels (vasculitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension).</p><p><em><u>Respiratory effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; contraction of the lungs that causes temporary obstruction of the airways (bronchospasm),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing (dyspnea),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleed (epistaxis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma attack.</p><p><em><u>Digestive effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal perforations and ulcers,</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; inflammation of the pancreas (pancreatitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digestive bleeding (blood coming up to the mouth (haematemesis) or in the stool, black colored stool (melena). This type of bleeding becomes more frequent with higher doses,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach lining (gastritis).</p><p><em><u>Hepatobiliary effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe liver inflammation that can be fatal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of the skin or eyes).</p><p><em><u>Effects on the skin:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering, often associated with itching and burning sensation (hives) on the face with difficulty breathing (angioedema),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin reactions such as rash, blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s syndrome), DRESS syndrome, bullous skin reactions, exfoliative dermatitis, erythema multiforme),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strong skin reaction when skin is exposed to the sun or UV rays,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fixed drug eruption (may look like round or oval patches of redness and swelling of the skin), blistering, often associated with itching and burning sensation (hives),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vascular purpura resulting in haemorrhagic spots on the skin (Henoch-Schonlein),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; progressive detachment of the nail (onycholysis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of blistering, often associated with itching and burning sensation (chronic hives),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (alopecia).</p><p><em><u>Effects on the kidney:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal kidney filtration function (functional acute renal failure, nephrotic syndrome),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of certain kidney tissues (glomerulonephritis, interstitial nephritis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; necrosis of part of the kidney (papillary necrosis, acute tubular necrosis).</p><p><em><u>Reproductive effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased fertility in women.</p><p><em><u>General and administration site effects:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local adverse reactions (burning sensations) or tissue damage at the injection site,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; malaise,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site.</p><p><em><u>Effects on the biological test:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; positive antinuclear antibody test,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transitory or reversible elevation of bilirubin in the blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; platelet aggregation decreased and bleeding time increased.</p><p><u>If any of the side effects listed above occur, you must notify a doctor immediately and consider stopping</u> <u>treatment.</u></p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp; SFDA Call center : 19999</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website :<u>https://ade.sfda.gov.sa/</u></p></td></tr></tbody></table><p><strong>Other GCC States</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 25&deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the box after EXP. The expiry date refers to the last day of that month.</p><p><u>After opening: </u>the product should be used immediately.</p><p>Keep this medicine away from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is:<br />Piroxicam ................................................ 20.00 mg<br />For one ampoule<br />&bull; The other ingredients are:</p><p>Sodium dihydrate dihydrogen sulphate, nicotinamide, propylene glycol , ethanol, benzyl alcohol, sodium hydroxide, hydrochloric acid, water for injection (see section 2).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This medicine is in the form of solution for injection in ampoule of 1mL. Carton of 5 ampoules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO, AL-QASSIM PHARMACAEUTICAL PLANT, SAUDI ARABIA</p><p><strong>Manufacturer</strong></p><p>SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia</p><p>Under license from: Pfizer Inc, New York, U.S.A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الفئة الدوائية العلاجية: مضادات الالتهاب غير الستيرويدية &ndash; رمز نظام التصنيف الكيميائي العلاجي التشريحي (ATC): M01AC01&nbsp;</p><p>قبل أن يصف لك طبيبك بيروكسيكام،يجب أن يقيم الفوائد التي قد تعود عليك من استخدام هذا الدواء مقارنة بمخاطر الإصابة بالأعراض الجانبية. سيصف لك طبيبك بيروكسيكام فقط إذا لم يتم تخفيف الأعراض التي تعاني منها بشكل كاف باستخدام مضادات الالتهاب غير الستيرويدية (NSAIDs) الأخرى .</p><p>&nbsp;يستخدم محلول فلدين ۲۰ ملجم/مل المعبأ في أمبولات المخصص للحقن بوصفه علاجا قصير الأمد لتخفيف بعض الأعراض أثناء نوبات التهاب&nbsp; المفاصل الروماتويدي والتهاب الفقار المقسط (وهما حالتان روماتيزميتان تصيبان العمود الفقري)، مثل التورم والتيبس وألم المفاصل.</p><p>يستخدم هذا الدواء عن طريق الحقن عندما لا يمكن استخدام مساري التعاطي عبر الفم وعبر المستقيم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل )</strong><br />&nbsp;&bull; إذا كنت مصابًا بالحساسية تجاه المادة الفعالة أو تجاه أي من المكونات الأخرى لهذا الدواء، المدرجة في القسم ٦<br />&bull; إذا كنتِ حاملًا، من بداية الشهر السادس من الحمل (بعد ۲٤ أسبوعًا من انقطاع الحيض) ،<br />&bull; إذا كان لديك تاريخ من الإصابة بحالات الحساسية أو الربو التي يحفز ظهورها تناول هذا الدواء أو دواء آخر مشابه، خاصة مضادات الالتهاب غير الستيرويدية الأخرى، الأسبرين،<br />&bull; إذا كان لديك تاريخ من الإصابة بتفاعلات جلدية شديدة مثل التهاب الجلد التقشري (احمرار شديد للجلد مصحوب بتقشر الجلد في صورة<br />قشور أو طبقات)، والتفاعلات الحويصلية الفقاعية (متلازمة ستيفنز جونسون، وهي حالة يصاب فيها الجلد بنزيف مصحوب ببثور حمراء<br />وتآكل وتكوّن قشور) ومتلازمة ليل (حالة جلدية خطيرة تتسم بظهور بثور وانفصال الطبقة العليا للجلد) ،<br />&bull; في حالة وجود تاريخ من الإصابة بالقرح أو النزيف أو الانثقاب في المعدة أو الأمعاء ،<br />&bull; في حالة الإصابة الحالية أو السابقة باضطرابات هضمية (التهاب المعدة أو الأمعاء) تجعلك عرضة للإصابة باضطرابات نزفية مثل التهاب المستقيم والقولون النزفي أو مرض كرون أو السرطانات المعدية المعوية أو التهاب الرتج (التهاب حويصلات القولون او عدواها )،<br />&bull; في حالة تناول أسيتريتين،<br />&bull; في حالة الإصابة بقرحة نشطة في الاثني عشر أو المعدة،<br />&bull; في حالة الإصابة بمرض خطير بالقلب،<br />&bull; في حالة الإصابة بمرض خطير بالكبد،<br />&bull; في حالة الإصابة بمرض خطير بالكلى،<br />&bull; في حالة الأطفال البالغين من العمر أقل من ۱٥ عامًا،<br />&bull; في حالة الخضوع لجراحة تركيب مجازة أبهرية تاجية (جراحة قلب لتجاوز شريان متضيق) .<br />&bull; في حالة الرضّع المولودين مبكرًا وحديثي الولادة المولودين بعد اكتمال الحمل، اذا&nbsp; يحتوي هذا الدواء على كحول بنزيلي وبروبيلين<br />جليكول (انظر &quot;الاحتياطات عند استعمال محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل)&quot;)،<br />&bull; في حالة تناول ميفامورتيد.<br />إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك،ينبغي عليك عدم تناول بيروكسيكام. أبلغ طبيبك على الفور إذا انطبقت عليك أي من هذه الحالات .<br />إذا كنت غير متأكد بشأن أي أمر، فمن الضروري أن تستشير طبيبك أو الصيدلي.</p><p><strong>الاحتياطات عند استعمال محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل )</strong><br />تحدث إلى طبيبك أو الصيدلي قبل تناول محلول فلدين ۲۰ ملجم/ مل المعبأ في قارورة والمخصص للحقن (عن طريق العضل) .</p><p><u><strong>تحذيرات</strong></u><br />ينبغي تناول هذا الدواء فقط تحت إشراف طبي.</p><p><br />كن حذرًا عند استخدام محلول فلدين ۲۰ ملجم/ مل المعبأ في قارورة والمخصص للحقن (عن طريق العضل) واحرص دومًا على إبلاغ طبيبك قبل استخدامه .<br />&nbsp;كما هو الحال مع جميع مضادات الالتهاب غير الستيرويدية (NSAIDs) ،يمكن أن يسبب محلول فلدين ۲۰ ملجم/ مل المخصص للحقن (عن طريق العضل) تفاعلات معدية معوية خطيرة، مثل الألم أو النزيف أو القرحة أو الانثقاب. إن استعمال جرعات أكبر من ۲۰ ملجم في اليوم يزيد من خطر حدوث الأعراض الجانبية المعدية المعوية.</p><p><br />قد تتسبب الأدوية مثل محلول فلدين ۲۰ ملجم/ مل المخصص للحقن (عن طريق العضل) في زيادة خطر الإصابة بالأزمة القلبية (&quot;احتشاء عضلة القلب&quot;) أو السكتة الدماغية. يزداد الخطر عندما تكون الجرعات المستخدمة أعلى ومدة العلاج أطول. لا تتجاوز الجرعات ولا مدة العلاج الموصى بها.</p><p><br />إذا كنت تعاني من مشكلات بالقلب أو إذا كنت قد أصبت من قبل بسكتة دماغية أو إذا كنت تعتقد أن لديك عوامل خطر للإصابة بهذا النوع من<br />المرض (على سبيل المثال إذا كنت مصابًا بضغط الدم المرتفع أو داء السكري أو ارتفاع مستويات الكوليسترول أو إذا كنت مدخنًا)، فأبلغ طبيبك او الصيدلي .</p><p><br />أبلغ طبيبك:<br />&bull; إذا كان لديك تاريخ من الإصابة بالربو المصحوب بالالتهاب الانف&nbsp;المزمن او التهاب الجيوب الانفية او وجود سلائل في الانف .<br />&nbsp;يمكن أن يسبب استعمال هذا الدواء الإصابة بنوبة ربو، خاصة لدى بعض المرضى المصابين بالحساسية تجاه الأسبرين او مضادات الالتهاب غير الستيرويدية (انظر قسم &quot;موانع استعمال محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل)&quot;) ،</p><p><br />أوقف العلاج فورًا وأبلغ طبيبك:<br />&bull; إذا أصبت بألم في المعدة أو أي علامة على وجود نزيف معدي معوي (خروج دم من الفم أو وجود دم في البراز أو تلوّن البراز باللون الاسود)،<br />&bull; إذا أصبت بتفاعل حساسية يظهر على شكل طفح جلدي أو تورم في الوجه أو أزيز أو صعوبة في التنفس ،<br />&bull; في حالة وجود اضطرابات في وظائف الكبد أو تفاقم حالتها .<br />&bull; إذا عانيت من طفح جلدي أو أعراض جلدية،ينبغي أن تتوقف فورًا عن تناول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل)، واطلب المشورة الطبية على وجه السرعة وأخبر طبيبك أنك تتناول هذا الدواء .</p><p><u><strong>احتياطا ت</strong></u><br />يتوفر هذا الدواء في أشكال جرعات أخرى يمكن أن تكون أكثر ملاءمة .<br />من الضروري أن تبلغ الطبيب الذي يصف لك الوصفة الطبية إذا كنت مصابًا بأيٍ من الحالات التالية، حيث سيتطلب هذا تعديل الجرعة :<br />&bull; إذا كان لديك تاريخ من الإصابة بأحداث هضمية (نزيف في القناة الهضمية، فتق حجابي، تاريخ من الإصابة بقرحة في المعدة أو الاثني عشر)،<br />&bull; إذا كنت مصابًا بمرض في القلب أو الكبد أو الكلى.</p><p><br />إذا كان عمرك أكبر من ۷۰ عامًا، فقد يتعين على طبيبك تقليل مدة العلاج ورؤيتك بمعدل أكثر تكررًا أثناء فترة استعمال بيروكسيكام.</p><p><br />إذا كان عمرك أكبر من ۷۰ عامًا أو إذا كنت تتناول أدوية مثل الستيرويدات القشرية أو أدوية أخرى مضادة للاكتئاب تُسمى مثبطات استرداد&nbsp;السيروتونين الانتقائية (SSRIs)<br />أو حمض الأسيتيل ساليسيليك لمنع تكوّن الجلطات الدموية، أو إذا كنت تستهلك الكحوليات، فقد يصف لك طبيبك دواءً لحماية الغشاء المخاطي لمعدتك بالتزامن مع محلول فلدين ۲۰ ملجم/ مل المعبأ في امبولة&nbsp;المخصص للحقن (عن طريق العضل) .</p><p><br />يجب ألا تتناول هذا الدواء إذا كان عمرك أكبر من ۸۰ عاماً.</p><p><br />إذا كنت تعاني أو سبق لك أن عانيت من مشكلات طبية أو حالات حساسية، أو إذا لم تكن متأكدًا مما إذا كان ينبغي عليك استخدام بيروكسيكام،<br />يرجى إبلاغ طبيبك قبل استخدام هذا الدواء .</p><p><br />تأكد من أنك قد أخبرت طبيبك بجميع الأدوية الأخرى التي قد تكون تتناولها، بما في ذلك تلك التي قمت بشرائها دون وصفة طبية .<br />إذا كنت غير متأكد بشأن أي أمر، فلا تتردد في استشارة طبيبك أو الصيدلي.</p><p><br /><strong>الأطفال والمراھقو ن</strong><br />لا ينطبق .<br /><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول اي ادوية اخرى&nbsp;أو تناولت مؤخرًا أو قد تتناول .</p><p>يرجى إبلاغ طبيبك بالأدوية الأخرى التي تتناولها أو تناولتها مؤخرًا (أثناء الأسبوع الماضي)، بما في ذلك الأدوية التي قمت بشرائها بنفسك دون وصفة طبية .<br />يمكن أن تتداخل بعض الأدوية في بعض الأحيان مع نشاط أدوية أخرى. قد يحدّ طبيبك من استخدامك لبيروكسيكام أو الأدوية الأخرى أو قد يعطيك دواءً مختلفًا.</p><p>من المهم بشكل خاص أن تبلغ طبيبك بالتالي:<br />&bull; إذا كنت تتناول ميفامورتيد،<br />&bull; إذا كنت تتناول أسيتريتين،<br />&bull; إذا كنت تتناول حمض الأسيتيل ساليسيليك أو مضاد التهاب غير ستيرويدي آخر لتخفيف الألم ،<br />&bull; إذا كنت تتناول الستيرويدات القشرية التي تؤخذ عبر الفم، وهي أدوية تُعطى لعلاج حالات متعددة مثل الحساسية واختلال التوازن الهرموني،<br />&bull; إذا كنت تتناول مضادات التخثر مثل مشتقات من نوع الكومارين (وارفارين) ومضادات التخثر التي تؤخذ عبر الفم مباشرة (على سبيل المثال أبيكسابان، دابيجاتران، ريفاروكسابان) لمنع تكوّن الجلطات الدموية،</p><p>&bull; إذا كنت تتناول أدوية معينة مخصصة لعلاج الاكتئاب تُسمى مثبطات استرداد السيروتونين الانتقائية (SSRIs), ليثيوم،<br />&bull; إذا كنت تتناول أدوية مثل حمض الأسيتيل ساليسيليك لمنع تكدس الصفيحات الدموية،</p><p>إذا كنت تتناول ميثوتريكسات،<br />&bull; إذا كنت تتناول مركبات الهيبارين،<br />&bull; إذا كنت تتناول عوامل أخرى حافظة للبوتاسيوم،<br />&bull; إذا كنت تتناول بيميتريكسيد (يستخدم لعلاج سرطان الرئة) ،<br />&bull; إذا كنت تتناول سيكلوسبورين، تاكروليموس (يستخدمان لخفض دفاعات الجسم في حالة عمليات الزرع أو بعض الأمراض الجلدية) ،<br />&bull; إذا كنت تتناول أدوية لعلاجالضغط المرتفع ،<br />&bull; إذا كنت تتناول مدرات البول،<br />&bull; إذا كنت تتناول ديفيراسيروكس ،<br />&bull; إذا كنت تتناول تينوفوفير ديسوبروكسيل،<br />&bull; إذا كنت تتناول حمض النيكوتينيك،<br />&bull; إذا كنت تتناول أدوية تتسبب في حدوث تفاعل انسحاب ،<br />&bull; إذا كنت تتناول مناهضات فيتامين K</p><p>&bull; إذا كنت تتناول مثبطات أكسيداز أحادي الأمين (MAOIs)&nbsp;غير القابلة للعكس<br />&bull; إذا كنت تتناول الإنسولين،<br />&bull; إذا كنت تتناول المهدئات،<br />&bull; إذا كنت تتناول ميتفورمين،<br />&bull; إذا كنت تتناول السلفاميدات الخافضة لسكر الدم ،<br />&bull; إذا كنت تتناول مضادات تكدس الصفائح الدموية،<br />&bull; إذا كنت تتناول كوبيميتينيب،<br />&bull; إذا كنت تتناول العقاقير الأدرينالينية السيروتونينية المختلطة ،<br />&bull; إذا كنت تتناول نيكورانديل.<br /><strong>تناول محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل) مع الطعام والشرا ب</strong><br />لا ينطبق .<br /><strong>الحمل والرضاعة والخصوبة&nbsp;</strong><br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول أي<br />دواء .<br /><u><strong>الحمل</strong></u><br />قبل بداية الشهر السادس من الحمل (حتى الأسبوع ۲٤ من انقطاع الحيض)، ينبغي ألا تتناولي هذا الدواء إلا في حالات الضرورة الحتمية التي يحددها طبيبك، وذلك نظرًا لخطر حدوث الإجهاض أو التشوهات المحتمل. في هذه الحالة،ينبغي أن تكون الجرعة أقل مايمكن وأن تكون مدة العلاج قصيرة قدر الإمكان.ينبغي لمتخصصي الرعاية الصحية أن يضعوا في الاعتبار مراقبة السائل الأمينوسي بالموجات فوق الصوتية إذا امتد العلاج بمضادات الالتهاب غير الستيرويدية لأكثر من ٤۸ ساعة، وإيقاف العلاج بمضادات الالتهاب غير الستيرويدية إذا اكتُشف نقصًا في السائل الأمينوسي.</p><p>&nbsp;</p><p><strong>بعد مرور ۱۲ أسبوعا دون حيض, قد يسبب هذا الدواء&nbsp;</strong>&nbsp;مشكلات بالكليتين لدى طفلك، إذا تناولته لعدة أيام، وهو ما قد يؤدي إلى انخفاض مستوى&nbsp;السائل الأمنيوسي المحيط بالطفل (قلة السائل السلوي). قديحدث تضيق الأوعية الدموية (انقباض القناة الشريانية) في قلب طفلك . إذا كنت بحاجة إلى عدة أيام من العلاج، فقد يوصيك طبيبك بإجراء مراقبة إضافية .</p><p><br /><strong>من بداية الشهر&nbsp;السادس وحتى نهاية الحمل </strong>(بعد الأسبوع ۲٤ من انقطاع الحيض)،يمنع استعمال هذا الدواء، ممايعني أنه يجب عليكِ ألا تتناولي<br />هذا الدواء، لأن آثاره على طفلكِ، وخاصة على قلبه و/أو رئتيه و/أو كليتيه، يمكن أن تكون خطيرة أو حتى مميتة، حتى مع استخدام جرعة فردية .</p><p>وقد يؤثر ذلك أيضا فيك وفي طفلك بزيادة النزيف ويؤدي إلى تأخر الولادة أو استغراقها لوقت أطول من المتوقع.<br />قد يعبر الكحول البنزيلي من خلال الحاجز المشيمي (انظر أدناه) .<br />إذا حدث أن تناولتِ هذا الدواء أثناء الحمل، فتحدثي مع طبيب التوليد- أمراض النساء الخاص بكِ فورًا لضمان توفر المراقبة الملائمة لكِ إذا لزم الأمر.<br /><u><strong>الرضاعة الطبيعية</strong></u><br />نظرًا لأن هذا الدواء يمر إلى لبن الثدي، فلايوصى باستخدامه أثناء فترة الرضاعة الطبيعية.<br /><u><strong>الخصوبة</strong></u><br />كما هو الحال مع جميع مضادات الالتهاب غير الستيرويدية &nbsp;(NSAIDs),&nbsp;قد يغير هذا المنتج الدوائي مستوى الخصوبة لدى السيدات ويتسبب في صعوبات<br />تعوق الحمل، ويكون تأثيره قابلًا للعكس عند إيقاف العلاج. أخبري طبيبكِ إذا كنتِ تخططين للحمل أو تواجهين صعوبات في حدوث الحمل .</p><p><strong>تأثير محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل) على القيادة واستخدام الآلا ت</strong><br />في حالات نادرة، يمكن لاستخدام هذا الدواء أن يسبب الدوار والنعاس .</p><p><strong>معلومات هامة حول بعض مكونات محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل )<br />يحتوي محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل) على كحول بنزيلي، وإيثانول، وبروبيلين جليكول، وصوديوم.</strong><br />يحتوي هذا الدواء على ۲۰ ملجم من الكحول البنزيلي في كل أمبولة.<br />يمكن أن يؤدي الكحول البنزيلي إلى حدوث تفاعلات حساسية .<br />إن الكحول البنزيلي، وهو مادة حافظة، يرتبط بخطر وقوع أحداث ضارة خطيرة، بما في ذلك مشكلات التنفس (تُسمى &quot;متلازمة اللهاث&quot;)</p><p>والوفاة في الأطفال الصغار. على الرغم من أن كميات الكحول البنزيلي التي يتم توصيلها في الجرعات العلاجية المعتادة أقل بدرجة كبيرة من تلك التي<br />تنشأ بسببها حالة &quot;متلازمة اللهاث&quot;، فإن الحد الأدنى لكمية الكحول البنزيلي الذي قد تحدث فيه السمية غير معروف.</p><p>الرضّع المولودون مبكرًا والرضّع ذوو الوزن المنخفض عند الولادة هم عرضة أكثر للإصابة بالسمية. قد تسبب هذه المادة أيضًا تفاعلات سامة وتفاعلات حساسية ل دى<br />الرضّع والأطفال الذین تصل أعمارھم إلى ۳ أعوام (انظر &quot;موانع استعمال محلول فلدین ۲۰ ملجم/مل المخصص للحقن (عن طریق العضل)&quot;) .</p><p>أخبري طبیبكِ أو الصیدلي إذا كنتِ حاملًا أو ترضعین رضاعة طبیعیة. قد تتراكم الكمیات الكبیرة من الكحول البنزیلي في جسمكِ وتُسبب آثارًا<br />جانبیة (تُسمى &quot;الحماض الأیضي&quot;).<br />أخبر طبیبك أو الصیدلي إذا كنت تعاني من مرض في الكلى أو الكبد. قد تتراكم الكمیات الكبیرة من الكحول البنزیلي في جسمك وتُسبب آثار ا<br />جانبیة (تُسمى &quot;الحماض الأیضي&quot;).</p><table border="1" cellspacing="1" cellpadding="1" style="width:723px"><tbody><tr><td style="width:719px">۱۲ % (حجم/حجم) أو ۱۰۰ ملجم من الكحول في كل أمبولة . . تحذیر: یبلغ محتوى الكحول في المحلول ٦</td></tr></tbody></table><p>۲ . ۱۲ % من الحجم، أي ما یصل إلى ۱۰۰ ملجم لكل قارورة، بما یكافئ ٤۷ . یحتوي ھذا الدواء على إیثانول (كحول) بنسبة ۲<br />۱. مل من النبیذ لكل أمبولة . . مل من الجعة أو ۰۳<br />یُعد استخدام ھذا الدواء خطیرًا في حالة الأشخاص المدمنین للكحولیات وینبغي وضع ذلك في الاعتبار في حالة السیدات الحوامل أو اللاتي<br />یرضعن رضاعة طبیعیة والأطفال والفئات الأكثر تعرضًا للخطر، مثل أولئك المصابین بقصور كبدي أو صرع .<br />یحتوي ھذا الدواء على ٤۰۰ ملجم من البروبیلین جلیكول في كل قارورة وقد یسبب أعراضًا مشابھة للأعراض التي یسببھا الكحول .<br />إذا كنتِ حاملًا أو ترضعین رضاعة طبیعیة، فلا تستخدمي ھذا الدواء إلا بناءً على مشورة طبیبكِ. قد یشرع طبیبكِ في إجراء فحوصات إض افیة<br />أثناء تناول ھذا الدواء.<br />إذا كنت مصابًا بمرض في الكبد أو الكلى، فلا تستخدم ھذا الدواء إلا إذا نصحك طبیبك باستخدامھ. قد یشرع طبیبك في إجراء فحوصات تكمیلیة<br />أثناء تناول ھذا الدواء.<br />یحتوي ھذا الدواء على أقل من ۱ ملیمول ( ۲۳ ملجم) من الصودیوم لك ل قارورة، أي أنھ &quot;خالٍ من الصودیوم&quot; بشكل أساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرص دومًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.<br /><strong><u>الجرعات</u><br />المرضى البالغون والمسنون :</strong><br />الحد الأقصى للجرعة اليومية هو ٢٠ مليجرام )أمبولة واحدة( من بيروكسيكام في صورة جرعة فردية يومية.</p><p>قد يصف لك طبيبك دواءً آخر بالتزامن مع بيروكسيكام لحماية معدتك وأمعائك من الآثار الجانبية المحتملة .في جميع الحالات، اتبع وصفة طبيبك بدقة .</p><p><br /><u><strong>طريقة الاستعمال</strong></u><br />مسار الحقن عن طريق العضل .<br />يمكن أن يتم حقن هذا المنتج إما بمحقنة زجاجية أو بمحقنة مخصصة للاستعمال مرة واحدة .قم بحقن الدواء بمجرد أن تقوم بتعبئة المحقنة .<br />يجب إعطاء الحقن بعمق وببطء في ظل ظروف معقمة تمامًا في الربع العلوي الخارجي من الردف. في حالة الحقن المتكرر، قم بتغيير جانب الحقن في كل مرة .<br />من المهم أن تسحب المكبس إلى الخلف قليلًا قبل حقن المنتج الدوائي لتتأكد من أن طرف الإبرة لم يدخل في أي أوعية دموية .<br />إذا كان الحقن مؤلمًا جدًا، فأوقف الحقن على الفور.<br />إذا كنت قد خضعت لعملية استبدال مفصل الورك، فقم بإعطاء الحقنة في الجانب المقابل .</p><p><br /><u><strong>معدل الاستعمال</strong></u><br />حقنة واحدة يوميًا.<br />في جميع الحالات، اتبع تعليمات طبيبك بدقة .</p><p><br /><u><strong>مدة العلا ج</strong></u><br />يستمر العلاج لمدة يومين أو ۳ أيام تقريبًا. بعد ذلك، استكمل العلاج عبر الفم أو عبر المستقيم .<br />في جميع الحالات، اتبع تعليمات طبيبك بدقة .<br /><strong>الجرعة الزائدة من محلول فلدين ۲۰ ملجم/مل المخصص للحقن(عن طريق العضل )</strong><br />استشر طبيبك أو الصيدلي على الفور.<br /><strong>نسيان تناول جرعة محلول فلدين ۲۰ ملجم/مل المخصص للحقن(عن طريق العضل)</strong><br />لا ينطبق .<br /><strong>&nbsp;التوقف عن تناول محلول فلدين ۲۰ ملجم/مل المخصص للحقن (عن طريق العضل )</strong><br />لا ينطبق .<br />إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، لكنھا لا تصيب الجميع.<br />قد تتسبب الأدوية مثل محلول فلدين ۲۰ ملجم/مل المخصص للحقن في زيادة خطر الإصابة بالأزمة القلبية (&quot;احتشاء عضلة القلب&quot;) أو السكتة<br />.الدماغية<br />:قد يحدث ما يلي&nbsp;<br /><strong>:الآثار الضارة الشائعة (قد تصیب ما یصل إلى شخص واحد من بین كل ۱۰ أشخاص )</strong><br /><u>:</u>&nbsp;ا<u>لآثار على الأيض والتغذية</u></p><ul><li>فقدان الشهية (القهم)&nbsp;</li></ul><p dir="ltr"><u>:الآثار على الجهاز العصبي</u></p><ul><li>&nbsp;الصداع، الدوار، النعاس، الدوخة&nbsp;</li></ul><p dir="ltr"><u>:الآثار على الأذن</u></p><ul><li>طنين في الأذنين</li></ul><p dir="ltr"><u>:الآثار على الجهاز الهضمي</u></p><ul dir="ltr"><li dir="rtl">&nbsp;الشعور بثقل في البطن، الغثيان، الإمساك، الشعور بانزعاج في البطن، امتلاء البطن بالغازات، ألم البطن، الإسهال، القيء، عسر الهضم&nbsp;</li></ul><p>ا<u>لآثار على الجلد</u>:</p><ul><li>الطفح الجلدي، الحكة&nbsp;</li></ul><p><u>:الآثار العامة&nbsp;</u></p><ul><li>&nbsp;تورم أجزاء من الجسم نتيجة لارتشاح السوائل في الأنسجة (التورم، وخاصة تورم الساقين)&nbsp;</li></ul><p><u>الآثار على نتائج الاختبارات الحيوية&nbsp;:</u></p><ul><li>&nbsp;ارتفاع قابل للعكس في مستويات نيتروجين يوريا الدم، زيادة مؤقتة أو قابلة&nbsp;للعكس&nbsp;في مستويات ناقلة أمين مصل الدم (إنزيمات موجودة(داخل الخلايا</li><li>انخفاض في الهيموجلوبين (بروتين موجود في خلايا الدم الحمراء يحمل الأكسجين إلى الأنسجة ويمنح الدم لونه الأحمر) والهيماتوكريت(النسبة المئوية للحجم الذي تشغله خلايا الدم الحمراء مقارنة بإجمالي حجم الدم)&nbsp; غير&nbsp; مرتبط بنزيف معدي معوي ملحوظ</li></ul><p dir="ltr"><u>إذا حدث أي من الآثار الجانبية المذكورة أعلاه، يجب عليك إخطار طبيب على الفور والأخذ</u> <u>في الاعتبار إيقاف العلاج</u><br /><strong>الآثار الضارة غير الشائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰&nbsp; &nbsp; &nbsp; &nbsp; شخص)&nbsp;&nbsp;</strong><br />:ا<u>لآثار على العينين</u></p><ul><li>تغيم الرؤية</li></ul><p dir="ltr"><u>&nbsp;:الآثار القلبية</u></p><ul><li>الشعور بضربات القلب (الخفقان)&nbsp;</li></ul><p dir="ltr">:<u>الآثار على الجهاز الهضمي</u></p><ul><li>التهاب في الفم (التهاب الفم)</li></ul><p dir="ltr"><u>:الآثار على الاختبارات الحيوية </u></p><ul><li>ارتفاع قابل للعكس في مستويات الكرياتينين في الدم، (قد تكون علامة على مشكلة&nbsp;&nbsp;في الكلى)</li></ul><p dir="ltr"><u>إذا حدث أي من الآثار الجانبية المذكورة أعلاه، يجب عليك إخطار طبيب على الفور والأخذ</u>&nbsp;<u>في الاعتبار إيقاف العلاج&nbsp;.</u><br />ا<strong>لآثار الضارة ذات معدل التكرار غير المعروف (لايمكن تقدیر معدل التكرار من البيانات المتاحة</strong>)&nbsp;<br /><u>:الآثار على الدم&nbsp;</u></p><ul dir="ltr"><li dir="rtl">&nbsp;انخفاض غير طبيعي في مستويات بعض خلايا الدم، مما قد ينتج عنه شحوب أو إرهاق شديد (خلايا الدم الحمراء)، أو علامات للإصابة بعدوى أو بحمى غير مبررة (خلايا الدم البيضاء)، أو نزيف من الأنف أو اللثة (الصفيحات&nbsp;الدموية)، أو ارتفاع غير طبيعي في مستويات خلايا الدم الأخرى (اليوزينيات)&nbsp;</li></ul><p><u>الآثار على الجهاز المناعي:</u></p><ul><li>تفاعلات حساسية شديدة (تفاعلات تأقية)</li><li>تفاعلات حساسية شديدة مرتبطة بظهور الأجسام المضادة (داء المصل)</li></ul><p dir="ltr"><u>:الآثار على الأيض والتغذية </u></p><ul><li dir="rtl">&nbsp;ارتفاع غير طبيعي في مستويات جلوكوز الدم (فرط جلوكوز الدم)&nbsp;</li><li dir="rtl">انخفاض غير طبيعي في مستويات جلوكوز الدم (نقص جلوكوز الدم)&nbsp;</li><li dir="rtl">&nbsp;احتباس السوائل، احتباس الصوديوم</li><li dir="rtl">ارتفاع مستوى البوتاسيوم في الدم (فرط بوتاسیوم الدم)&nbsp;</li></ul><p>&nbsp;</p><p><u>الآثار على الجهاز العصبي :</u></p><ul><li dir="rtl">&nbsp;تيبس الرقبة المصحوب بالحمى وأحيانًا الغيبوبة (التهاب السحايا العقيم)</li><li dir="rtl">اضطراب الحساسية الذي يتضمن الشعور باللسع، والخدر، والوخز في أحد الأعضاء الطرفية، عادةً في الجانب الطرفي(التنميل)</li></ul><p dir="ltr"><u>:الآثار على العينين</u></p><ul><li>تهيج العين، تورم العينين</li></ul><p dir="ltr"><u>:الآثار على الأذن&nbsp;</u></p><ul><li>&nbsp;ضعف السمع&nbsp;</li></ul><p dir="ltr"><u>:الآثار على الأوعية الدموية</u></p><ul><li>&nbsp;التهاب حاد في جدران الأوعية الدموية (التهاب الأوعية الدموية)،ضغط الدم المرتفع (ارتفاع ضغط الدم)&nbsp;</li></ul><p dir="ltr"><u>:الآثار التنفسية</u></p><ul><li>&nbsp;انقباض الرئتين الذي يسبب الانسداد المؤقت للمجاري الهوائية (التشنج القصبي)</li><li>&nbsp;صعوبة التنفس (ضيق التنفس)</li><li>&nbsp;نزيف الأنف (الرعاف)&nbsp;</li><li>&nbsp;نوبة ربو&nbsp;</li></ul><p dir="ltr"><u>:الآثار على الجهاز الھضمي </u></p><ul><li>&nbsp;القرح والانثقابات المعدية المعوية&nbsp;</li><li>&nbsp;التهاب البنكرياس</li><li>نزيف في الجهاز الهضمي (خروج الدم من الفم (قيء دموي) أو وجود دم في البراز، أو تلوُّن البراز باللون الأسود (التغوط الأسود) يزداد معدل حدوث هذا النوع من النزيف مع تلقي جرعات اعلى</li><li>التهاب بطانة المعدة (التهاب المعدة)</li></ul><p><u>الآثار الكبدية الصفراوية</u>&nbsp;<u>&nbsp;:</u></p><ul><li>التهاب الكبد الشديد الذي يمكن أن يكون مميتًا</li><li>اليرقان (اصفرار الجلد أو العينين)</li></ul><p><u>الآثار على الجلد&nbsp;:</u></p><ul><li>&nbsp;تبثر، غالبًا ما يكون مصحوبًا بحكة وشعور بالحرقان (شرى) على الوجه مع صعوبة التنفس (التورم الوعائي)</li><li>&nbsp;تفاعلات جلدية خطيرة مثل الطفح الجلدي، او تبثر أو تقشّر الجلد (متلازمة ستيفنز-&nbsp; جونسون، تقشّر الأنسجة المتموتة البشروية التسممي(متلازمة لايل)&nbsp; , &nbsp;متلازمة التفاعل الدوائي المصحوب بفرط اليوزينيات واعراض جهازية (DRESS)(تفاعلات جلدية فقاعية، التهاب الجلد&nbsp;التقشري،البقع الحمراء عديدة الاشكال ) ،</li><li>تفاعل جلدي شديد عند تعرض الجلد لأشعة الشمس أو للأشعة فوق البنفسجية&nbsp;</li><li>الطفح الدوائي الثابت (قد يظهر بقعًا جلد ية حمراء دائرية أو بيضاوية الشكل وتورم الجلد)، تبثر غالبًا ما يكون مصحوبًا بالحكة والشعور بالحرقان (الشرى)</li><li>&nbsp;الفرفرية الوعائية التي تؤدي إلى ظهور بقع نزفية على الجلد (هينوخ شونلاين)</li><li>&nbsp;انفصال الأظافر التقدمي (انفكاك الأظافر)&nbsp;</li><li>&nbsp;تفاقم حالة التبثر، وغالبًا ما يكون مصحوبًا بالحكة والشعور بالحرقان (الشرى المزمن)&nbsp;</li><li>&nbsp;تساقط الشعر (الثعلبة) .</li></ul><p><u>الآثار على الكلى:</u><br />&bull; اضطراب وظيفة ترشيح الكلى (الفشل الكلوي الوظيفي الحاد، المتلازمة الكلوية) ،<br />&bull; التهاب بعض أنسجة الكلى (التهاب كبيبات الكلى، التهاب الكلية الخلالي)،<br />&bull; نخر في جزء من الكلى (نخر الحليمات الكلوية، النخر النبيبي الحاد) .<br /><u>الآثار على الجهاز التناسلي :</u><br />&bull; انخفاض الخصوبة في السيدات .<br /><u>الآثار الجانبية العامة والمتعلقة بموضع الاستعمال :</u><br />&bull; تفاعلات ضارة موضعية (شعور بالحرقان) أو تلف الأنسجة في موضع الحقن،<br />&bull; التوعك،<br />&bull; ألم في موضع الحقن .<br /><u>الآثار على نتائج الاختبارات الحيوية :</u><br />&bull; نتيجة إيجابية لاختبار الأجسام المضادة للنواة،<br />&bull; ارتفاع عابر أو قابل للعكس في مستوى البيليروبين في الدم،<br />&bull; انخفاض تراكم الصفائح الدموية وزيادة مدة النزيف .<br /><u>إذا حدث أي من الآثار الجانبية المذكورة أعلاه، يجب عليك إخطار طبيب على الفور والأخذ في الاعتبار إيقاف العلاج .</u></p><p><br />ا<u><strong>لإبلاغ عن الأعراض الجانبية</strong></u><br />إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة .<br />بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء .<br />للإبلاغ عن الأعراض الجانبية<br /><strong>المملكة العربية السعودية&bull; </strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>المركز الوطني للتيقظ الدوائي<br />&bull; مركز الاتصال: ۱۹۹۹۹<br />&bull; البريد الإلكتروني : npc.drug@sfda.gov.sa<br />&bull; الموقع الإلكتروني :https://ade.sfda.gov.sa/</td></tr></tbody></table><p dir="ltr"><strong>دول الخليج الأخر ى</strong></p><table border="1" cellspacing="1" cellpadding="1" dir="ltr" style="width:500px"><tbody><tr><td>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة&nbsp;</td></tr></tbody></table><p dir="ltr">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال. يحفظ عند درجة حرارة اقل من ۲٥ درجة مئوية .<br />&nbsp;لا تستخدم فلدين بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية بعد الرمز&nbsp;&quot;EXP&quot;<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور .<br /><u>بعد الفتح</u>:ينبغي استخدام المنتج على الفور .<br />احتفظ بهذا الدواء بعيدًا عن الضوء .</p><p>لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد<br />هذه الإجراءات على حماية البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot; المادة الفعالة هي:</p><p>بيروكسيكام .............................................. 20.00 ملجم</p><p>للامبولة الواحدة</p><p>المكونات الأخرى هي:</p><p>كبريتات ثنائي الهيدروجين ثنائي هيدرات الصوديوم، نيكوتيناميد، بروبيلين جليكول، إيثانول، كحول بنزيلي، هيدروكسيد الصوديوم، حمض<br />&nbsp;الهيدروكلوريك، ماء للحقن (انظر القسم ۲)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يأتي هذا الدواء في صورة محلول مخصص للحقن معبأ في امبولة بحجم ۱ مل.</p><p>عبوة كرتونية تحتوي على ٥ امبولات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق:</strong></p><p>سبيماكو، القصيم، المملكة العربية السعودية<br /><strong>الجهة المصنعة :</strong><br />سبيماكو، القصيم، المملكة العربية السعودية<br />بترخيص من شركة فايزر الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FELDENE 20 mg/ mL, solution for injection (IM)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piroxicam……….…………………………………………………………………………20.0 mg

For one Ampoule.
Excipient(s) with known effect: benzyl alcohol, propylene glycol, ethanol , sodium. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injectable solution (IM).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Piroxicam is indicated for the symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis. Because of its safety profile (see sections 4.2, 4.3 and 4.4), piroxicam should not be used in first-line treatment when a NSAID is indicated.</p><p>The decision to prescribe a drug containing piroxicam should be based on an assessment of the individual patient&rsquo;s overall risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intra-muscular route.</p><p><strong><u>Posology</u></strong></p><p>The prescription of products containing piroxicam should be initiated by physicians with experience in the diagnosis and treatment of patients with inflammatory or degenerative rheumatic diseases.</p><p>The maximum recommended daily dose is 20 mg (one ampoule).</p><p>Adverse effects may be minimised by using the minimum effective dose for the shortest duration necessary to control symptoms. The benefit and safety of the treatment should be reassessed within 14 days. If continued treatment is necessary, it must be accompanied by frequent revaluations.</p><p>Given that piroxicam has been shown to be associated with an increased risk of gastrointestinal complications, the need for possible combination therapy with gastro-protective agents (e.g. misoprostol or proton pump inhibitors) should be carefully considered, in particular for elderly patients.</p><p><strong><u>Frequency of administration</u></strong></p><p>The duration of the treatment is 2 to 3 days (this time allowing, if necessary, the switch of the therapy to the oral or rectal route).</p><p>The piroxicam injectable route is administered only when the oral or rectal route could not be used.</p><p><strong><u>CYP2C9 poor metabolizers</u></strong></p><p>&nbsp;</p><p>The risk of dose-related adverse events is higher, piroxicam should be administered with caution to patients known or suspected to be CYP2C9 poor metabolizers based on genotyping or history/previous experiences with other substrates CYP2C9. A dose reduction should be considered (see section 5.2).</p><p><strong><u>Method of administration</u></strong></p><p>This product can be injected either with a glass syringe or with a single-use syringe (polypropylene).</p><p>Injections must be performed in a strictly aseptic way in the external part of the top external quadrant of the buttock, deeply and slowly. When repeated, it is recommended to change side at each injection. It is important to aspire before injecting, in order to ensure that the point of the needle is not in a vessel.</p><p>In case of severe pain, the injection must be stopped immediately.</p><p>In case of hip prosthesis, the injection must be performed on the opposite side.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product is contraindicated in the following cases:
•	hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
•	pregnancy, from the start of the 6th month (beyond 24 weeks of amenorrhoea) (see section 4.6),
•	history of allergy or asthma triggered by taking piroxicam or substances with similar activity such as other NSAIDs, aspirin,
•	history of all types of serious allergic drug reactions, in particular skin reactions such as polymorphic erythema, Stevens-Johnson syndrome, and toxic epidermal necrolysis (Lyell syndrome),
•	concomitant use of acitretin (see section 4.5),
•	history of gastrointestinal ulcer, bleeding or perforation,
•	patients presenting with a history of gastrointestinal disorders that predispose them to bleeding disorders such as ulcerative colitis, Crohn’s disease, gastrointestinal cancers or diverticulitis,
•	patients presenting with a progressive peptic ulcer, an inflammatory gastrointestinal disorder or gastrointestinal bleeding,
•	severe hepato-cellular insufficiency,
•	severe uncontrolled heart failure,
•	severe renal insufficiency,
•	children under 15 years of age,
•	haemostasis symptoms or concomitant anticoagulant treatment (contra indication due to the Intra- Muscular route),
•	in preterm and term newborns, due to the presence of benzyl alcohol and propylene glycol (see section 4.4),
•	aorto-coronary bypass,
•	in combination with mifamurtide (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;<u>Special warnings</u></strong></p><p>The concomitant use of piroxicam with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided.</p><p>The onset of undesirable effects may be minimised by using the minimum effective dose for the shortest duration necessary to relieve the symptoms (see section 4.2 and paragraphs &ldquo;Gastrointestinal effects&rdquo; and &ldquo;Cardiovascular and cerebrovascular effects&rdquo; below).</p><p>The clinical benefit and tolerability should be re-evaluated periodically and treatment should be immediately discontinued at the first appearance of cutaneous reactions or relevant gastrointestinal events.</p><p>Patients with asthma combined with a chronic rhinitis, chronic sinusitis and/or nasal polyposis have a higher risk of allergic reaction when they take aspirin and/or NSAIDs compared to the general population.</p><p>The administration of this medicine may lead in an asthma crisis, particularly in some patients allergic to aspirin or NSAIDs (see section 4.3).</p><p><em><u>Gastrointestinal (GI) Effects: risk of GI Ulceration, Bleeding, and Perforation</u></em></p><p>NSAIDs, including piroxicam, can cause serious gastrointestinal events including bleeding, ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. The administration of doses greater than 20 mg per day increases the risk of adverse gastrointestinal reactions. Observational studies suggest that piroxicam may be associated with an increased risk of serious gastrointestinal toxicity as compared to other NSAIDs. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs.</p><p>NSAID exposures of both short and long duration have an increased risk of serious GI event.</p><p>Patients with significant risk factors for serious GI events should be treated with piroxicam only after careful evaluation of benefit/risk ratio (see sections 4.3 and below).</p><p>The possible need for combination therapy with gastro-protective agents (e.g. misoprostol or proton pump inhibitors) should be carefully considered (see section 4.2).</p><p><em><u>Serious GI Complications</u> </em></p><p><em><u>Identification of at-risk subjects</u></em></p><p>The risk for developing serious GI complications increases with age. Age over 70 years is associated with high risk of complications. The administration to patients over 80 years should be avoided.</p><p>Patients taking concomitant oral corticosteroids, selective serotonin reuptake inhibitors (SSRIs) or anti- platelet agents such as low-dose acetylsalicylic acid are at increased risk of serious GI complications (see below and section 4.5), as well as patients who consume alcohol. As with other NSAIDs, the use of piroxicam in combination with protective agents (e.g. misoprostol or proton pump inhibitors) must be considered for these at-risk patients.</p><p>Patients and physicians should remain alerted for signs and symptoms of GI ulceration and/or bleeding during piroxicam treatment. Patients should be asked to report any new or unusual abdominal symptom during treatment. If a gastrointestinal complication is suspected during treatment, piroxicam should be discontinued immediately and additional clinical evaluation and treatment should be considered.</p><p><em><u>Cardiovascular (CV) and cerebrovascular effects</u></em></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) that are potentially fatal. A relative increase in the risk seems to be similar in all patients, whether they present with known CV disease or risk factors for CV that could lead to a higher risk in terms of absolute incidence, due to the higher risk that they present with from the start. There are insufficient data to exclude such a risk for piroxicam.</p><p>Patients with uncontrolled hypertension, congestive heart failure, ischaemic heart disease, peripheral arterial disease and/or a history of cerebrovascular disease (including a transitory ischaemic accident) should only be treated with piroxicam after a careful evaluation of the benefit/risk ratio.</p><p>Patients suffering from a CV disease may present with an increased risk of the aggravation of cardiac insufficiency: doctors and patients must be warned of this risk, even in the absence of past CV</p><p>symptoms. Patients must, moreover, be informed of the signs and symptoms of serious cardiac toxicity and the actions to take if they occur (see section 4.3).</p><p>Similar consideration should be made before initiating longer-term treatment of patients with risk factors for CV events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p><em><u>Hypertension</u></em></p><p>As with all NSAIDs, piroxicam may lead to the onset of arterial hypertension or the increase in pre- existing hypertension, which could contribute to an increase in the incidence of CV effects. NSAIDs, including piroxicam, should be used with caution in patients with hypertension. Blood pressure should be closely monitored at the start and for the entire period of treatment.</p><p><em><u>Hepatic effects</u></em></p><p>Severe hepatic involvement (jaundice, serious or fatal hepatitis) have rarely been reported with piroxicam. If liver function abnormalities persist or worsen or if clinical signs of liver failure of general signs (eosinophilia, rash) appear, piroxicam should be stopped.</p><p><em><u>Skin reactions</u></em></p><p>Serious skin reactions, some of which have fatal outcomes, including drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome) have very rarely been reported during treatment with NSAIDs (see section 4.8). Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with history of piroxicam-related FDE. Potential cross reactivity might occur with other oxicams.</p><p>Studies have suggested that piroxicam may be associated with a higher risk of serious skin reactions compared with other non-oxicam NSAIDs. The incidence of these adverse effects appears to be more significant at the start of treatment with the latency period in most cases during the first month of treatment. Treatment with piroxicam should be stopped at the first appearance of a skin rash, mucosal lesions or any other sign of hypersensitivity.</p><p><em><u>Functional renal impairment</u></em></p><p>NSAIDs, by inhibiting the vasodilatory action of renal prostaglandins, are likely to cause functional renal impairment by decreasing glomerular filtration.</p><p>At the start of treatment, monitoring of diuresis and renal function is recommended in all patients presenting with the following risk factors:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elderly subjects,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; associated drugs such as ACE inhibitors, sartans and diuretics (see section 4.5),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypovolaemia irrespective of the cause,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiac insufficiency,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic renal impairment,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nephrotic syndrome,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus nephropathy,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decompensated liver cirrhosis.</p><p>Special attention should be paid when starting treatment with piroxicam in patients presenting with severe dehydration. Monitoring is also recommended in patients with kidney failure (see section 4.3).</p><p>Due to the significant elimination of piroxicam and its biotransformation products via the renal route, the administration of lower doses of piroxicam should be considered in patients with altered kidney function, and should be closely monitored (see sections 4.3 and 5.2).</p><p><em><u>Use with oral anticoagulants</u></em></p><p>The concomitant use of NSAIDs, including piroxicam, with oral anticoagulants increases the risk of gastrointestinal and non-gastrointestinal bleeding, and should be avoided. Oral anticoagulants include</p><p>warfarin/coumarin anticoagulants and direct oral anticoagulants (for example, apixaban, dabigatran, rivaroxaban). Anticoagulation/INR should be monitored in patients during anticoagulant treatment with warfarin/coumarin (see section 4.5).</p><p><em><u>Fluid retention</u></em></p><p>Fluid retention with possible oedema, hypertension or increased hypertension, and worsened cardiac insufficiency. Clinical monitoring is necessary at the start of treatment in the case of hypertension or cardiac insufficiency. A decreased effect in anti-hypertensive drugs is possible (see section 4.5).</p><p><em><u>Hyperkalaemia</u></em></p><p>Hyperkalaemia contributed by diabetes or treatment with hyperkalaemia-inducing medication (see section 4.5).</p><p>Blood potassium levels should be regularly monitored in these circumstances.</p><p><em><u>Elderly subjects</u></em></p><p>Elderly subjects present with an increased risk of undesirable effects from NSAIDs, in particular, gastrointestinal haemorrhages and perforations that could be fatal (see section 4.2).</p><p>When prescribing, the physician must take into account the fact that cases of secondary anovulatory infertility by non-rupture of De Graaf follicles, reversible upon discontinuation of treatment have been reported in patients treated chronically by some inhibitors synthesis of prostaglandins.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_12" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:66.35pt;margin-top:5.9pt;width:462.6pt;
  height:15.15pt;z-index:-15727616;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.4pt;margin-bottom:.0001pt'>Warning:<span
     style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:-.1pt'>
     </span>alcohol<span style='letter-spacing:-.2pt'> </span>content<span
     style='letter-spacing:-.05pt'> </span>of<span style='letter-spacing:-.2pt'>
     </span>the<span style='letter-spacing:-.2pt'> </span>solution<span
     style='letter-spacing:-.25pt'> </span>is<span style='letter-spacing:-.1pt'>
     </span>12.6°<span style='letter-spacing:-.2pt'> </span>(v/v)<span
     style='letter-spacing:-.2pt'> </span>or<span style='letter-spacing:-.05pt'>
     </span>100<span style='letter-spacing:-.1pt'> </span>mg<span
     style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.2pt'>
     </span>alcohol<span style='letter-spacing:-.05pt'> </span>per<span
     style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>Ampoule.</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="1" cellpadding="1" style="width:515px"><tbody><tr><td style="width:511px"><p>Warning: the alcohol content of the solution is 12.6&deg; (v/v) or 100 mg of alcohol per Ampoule.</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>This medicine contains 12.6% volume of ethanol (alcohol), i.e. up to 100 mg per Ampoule, which is equivalent to 2.47 mL of beer or 1.03 mL of wine per Ampoule. Using this medicine is dangerous for alcoholic subjects and this should be taken into consideration in women who are pregnant or breast- feeding, children and high-risk groups, such as those with liver failure or epilepsy.</p><p>The drug product contains 20 mg/ ampoule of benzyl alcohol per Ampoule. Benzyl alcohol can lead to allergic reactions.</p><p>Benzyl alcohol, a preservative, is linked with the risk of severe side effects including breathing problems (called &ldquo;gasping syndrome&rdquo; and death in young children. While at the usual therapeutic doses, the quantities of benzyl alcohol delivered are considerably less than doses at the origin of &ldquo;gasping syndrome&rdquo;, the minimum quantity of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol-induced toxicity depends on the quantity administered and the hepatic detoxification capacity of the product. In particular, there is an increased risk due to accumulation in young children. Premature infants and infants with a low birth weight have a greater risk of presenting with toxicity. Benzyl alcohol may also cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. FELDENE is contraindicated in children less than 15 years old (see section 4.3).</p><p>High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).</p><p>High volumes should be used with caution and only if necessary, especially in pregnant women because of the risk of accumulation and toxicity (metabolic acidosis) (see section 4.6).</p><p>This medicine contains 400 mg of propylene glycol per vial and can lead to similar symptoms to those caused by alcohol.</p><p>Even if propylene glycol has not shown any reproduction or development toxicity in animals or humans, it can reach the foetus and has been found in milk. Therefore, propylene glycol administration to pregnant or breast-feeding patients should be considered on a case-by-case basis (see section 4.6).</p><p>A medical supervision is required in patients with renal failure or impaired liver function, because diverse side effects assigned to propylene glycol have been reported as renal dysfunction (acute tubular necrosis), acute renal failure and hepatic dysfunction.</p><p>This medicine contains less than 1 mmol (23 mg) of sodium per vial, which means that it is essentially &ldquo;without sodium&rdquo;.</p><p><strong><u>Precautions for use</u></strong></p><p>This medicine is presented in several dose strength which might be more appropriate.</p><p>The occurrence of asthma crisis in some patients might be related to an aspirin or NSAID allergy (see section 4.3).</p><p>Particular attention should be given to patients with a history of hypertension and/or heart failure, cases of fluid retention and oedema have been reported in association with NSAID therapy.</p><p><strong><u>Slow CYP2C9 substrate metabolisers</u></strong></p><p>Precaution should be taken with patients who are known or suspected to be slow metabolisers of CYP2C9, based on the history of other CYP2C9 substrates, since there could be abnormally elevated plasma concentrations of piroxicam due to a decrease in metabolism (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Simultaneous administration of piroxicam with the following products requires careful monitoring of patient clinical and biological status.</p><p><strong><u>Contraindicated associations</u></strong></p><p><strong>+ Mifamurtide</strong></p><p>At high doses of NSAIDs, risk of less effective mifamurtide.</p><p><strong><u>Inadvisable combinations</u></strong></p><p><strong>+ Acetylsalicylic acid (at anti-inflammatory doses (&ge; 1 g per dose and/or &ge; 3 g per day) or at analgesic or antipyretic doses (500 mg per dose and/or &lt; 3 g per day)</strong></p><p>increased risk of digestive ulcers and bleeding.</p><p><strong>+ Oral anticoagulants</strong></p><p>NSAIDs, including piroxicam, are likely to enhance the effects of anticoagulants, such as coumarin-type derivatives (warfarin) and direct oral anticoagulants (for example, apixaban, dabigatran, rivaroxaban). Increase in the risk of haemorrhage from oral anticoagulant (aggression of the gastroduodenal mucosa by non-steroidal anti-inflammatories). Consequently, the concomitant use of piroxicam and anticoagulants should be avoided. If the association cannot be avoided, carry out close clinical, or even biological, monitoring (see section 4.4).</p><p><strong>+ Other non-steroidal anti-inflammatories (including aspirin and other salicylates)</strong></p><p>With other non-steroidal anti-inflammatories: increased risk of digestive ulcers and bleeding.</p><p>As with all NSAIDs, the use of piroxicam combined with acetylsalicylic acid or other NSAIDs, and the combination of several proprietary medicinal products containing piroxicam, must be avoided.</p><p>No data has made it possible to demonstrate the benefit of these combinations compared with piroxicam alone, and therefore the incidence of adverse effects is increased (see section 4.4).</p><p>Human studies have highlighted a reduced piroxicam plasma concentration of approximately 80% of the usual value during the concomitant administration of piroxicam and acetylsalicylic acid.</p><p><strong>+ Low-molecular-weight heparins and related agents (curative doses and/or elderly subjects)</strong></p><p>Increase in the risk of haemorrhage (aggression of the gastroduodenal mucosa by non-steroidal anti- inflammatories). If the combination cannot be avoided, close clinical monitoring.</p><p><strong>+ Unfractionated heparins (curative doses and/or elderly subjects)</strong></p><p>Increase in the risk of haemorrhage (aggression of the gastroduodenal mucosa by non-steroidal anti- inflammatories). If the combination cannot be avoided, close clinical monitoring.</p><p><strong>+ Lithium</strong></p><p>Increase of lithium plasma level, which might reach the toxic threshold (decrease of renal lithium excretion).</p><p>If the combination cannot be avoided, close monitoring of the lithium plasma levels and adaptation, during the combination and after the non-steroidal anti-inflammatory withdrawal, of the lithium doses.</p><p><strong>+ Methotrexate, used at doses upper than 20 mg/week</strong></p><p>Increase of the methotrexate particularly haematologic toxicity (decrease of its renal clearance by anti- inflammatory drugs).</p><p><strong>+ Nicorandil</strong></p><p>Increased risk of digestive ulcers and bleeding.</p><p><strong>+ Pemetrexed (in patients with weak to moderate renal function)</strong></p><p>Risk of increased toxicity of pemetrexed (decreased its renal clearance due to NSAIDs).</p><p><strong><u>Combinations to be used with caution</u></strong></p><p><strong>+ Angiotensin II receptor antagonists</strong></p><p>Acute renal failure in at-risk patients (elderly, dehydration, concomitant treatment with diuretics, renal function impairment), by decreasing glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are usually reversible. Moreover, the antihypertensive effect is decreased.</p><p>Hydrate the patient and monitor the renal function at treatment initiation and regularly during the combination.</p><p><strong>+ Cyclosporin</strong></p><p>Risk of additive nephrotoxic effects, particularly in elderly subjects.</p><p>Renal function should be monitored at the beginning of treatment with NSAIDs.</p><p><strong>+ Diuretics</strong></p><p>Risk of acute renal failure in at risk patients (elderly, dehydrated, on diuretics, with impaired renal function) by decrease of the glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are usually reversible. Moreover, the antihypertensive effect is decreased.</p><p>Hydrate the patient and monitor the renal function at treatment initiation and regularly during the combination.</p><p><strong>+ Converting-enzyme inhibitors</strong></p><p>Acute kidney failure in at-risk patients (elderly, dehydrated, on diuretics, with altered kidney function), from a decrease in glomerular filtration secondary to a decrease in synthesis of renal prostaglandins. These effects are generally reversible. Moreover, the antihypertensive effect is decreased.</p><p>Hydrate the patient and monitor the renal function at treatment initiation and regularly during the combination.</p><p><strong>+ Methotrexate, at low doses (lower than or equal to 20 mg/week)</strong></p><p>Increase of the haematological toxicity of methotrexate (decrease of its renal clearance by anti- inflammatory drugs).</p><p>Weekly blood monitoring during the first weeks following the association initiation. Close monitoring in case of renal impairment, even mild, and when administered to elderly subjects.</p><p><strong>+ Pemetrexed (in patients with normal renal function)</strong></p><p>Risk of increased toxicity of pemetrexed (decreased itsrenal clearance due to NSAIDs). Monitoring of renal function parameters.</p><p><strong>+ Tacrolimus</strong></p><p>Risk of additive nephrotoxic effects, particularly in elderly subjects.</p><p>Renal function should be monitored at the beginning of treatment with NSAIDs.</p><p><strong>+ Tenofovir disoproxil</strong></p><p>Increased risk of nephrotoxicity of tenofovir, notably with elevated doses of anti-inflammatories or in the presence of risk factors of kidney failure.</p><p>In the case of a combination, monitor kidney function.</p><p><strong><u>Combinations to take into account</u></strong></p><p><strong>+ Acetyl salicylic acid at anti-aggregate doses (from 50 mg to 375 mg daily taken once or several times)</strong></p><p>Increased risk of digestive ulcer and bleeding.</p><p>Piroxicam, like other NSAIDs, decreases platelet aggregation and prolongs bleeding time. This effect must be considered when determining bleeding time.</p><p>Piroxicam interferes with the antiplatelet effect of aspirin at low doses and may, therefore, interfere in the prophylactic action of aspirin in treating CV diseases.</p><p><strong>+ Platelet anti-aggregants</strong></p><p>Increased risk of bleeding, especially gastrointestinal.</p><p><strong>+ Other potassium-sparing agents</strong></p><p>Potentially fatal risk of increased hyperkalaemia.</p><p><strong><u>Risks related to hyperkalaemia</u></strong></p><p>Some medicinal products or therapeutic groups can favour the development of hyperkalaemia: potassium salts, potassium-sparing diuretics, angiotensin converting enzyme inhibitors, angiotensin II antagonists, non-steroidal anti-inflammatory drugs, heparins (low molecular weight or unfractionated), immunosuppressive drugs such as cyclosporine and tacrolimus, and trimethoprim.</p><p>This drug combination increases the risk of hyperkalaemia. This risk is especially important with potassium-sparing diuretics, particularly when combined or with potassium salts, while the combination of an ACE inhibitor and an NSAID, for example, is safer if the recommended precautions are implemented.</p><p>To know the risks and levels of constraints specific to potassium sparing drugs, refer to the interactions related to each substance.</p><p>However, some substances, such as trimethoprim, are not subject to specific interactions with regard to this risk. However, they can act as enabling factors when combined with other drugs such as those mentioned above.</p><p>The onset of hyperkalaemia may depend on the existence of co-related factors.</p><p><strong>+ Beta-blockers (except esmolol) (including eye drops)</strong></p><p>Reduction of the antihypertensive effect (inhibition of vasodilator prostaglandins by the non-steroidal anti-inflammatories).</p><p><strong>+ Deferasirox</strong></p><p>Increased risk of digestive ulcers and bleeding.</p><p><strong>+ Gluco-corticosteroids (except hydrocortisone)</strong></p><p>Increased risk of gastrointestinal ulcer and bleeding (see section 4.4).</p><p><strong>+ Non-fractionated heparins and low molecular weight heparins and related agents (preventive doses)</strong></p><p>Increased risk of bleeding.</p><p><strong>+ Selective serotonin re-uptake inhibitors (SSRI)</strong></p><p>Higher risk of bleeding (see section 4.4).</p><p><strong>+ Mixed adrenergic-serotonergic drugs</strong></p><p>Increased haemorrhagic risk.</p><p><strong>RELATED TO ETHANOL (excipient)</strong></p><p><strong><u>Contraindicated combinations</u></strong></p><p><strong>+ Acitretin</strong></p><p>In women of child-bearing age, the risk of the transformation of acitretin into etretinate, which is a potent teratogenic with a very long half-life (120 days), creates exposure to a major teratogenic risk in the event of pregnancy during treatment and in the 2 months following its discontinuation.</p><p><strong><u>Inadvisable combinations</u></strong></p><p>+&nbsp;&nbsp; <strong>Irreversible MAOIs (iproniazid)</strong></p><p>Increase in hypertensive effects and/or hyperthermia from tyramine, which is present in certain alcoholic beverages (chianti, certain beers, etc.).</p><p>Avoid taking this medicine with MAOIs.</p><p><strong>+&nbsp;&nbsp; Insulin</strong></p><p>Increase in hypoglycaemic reaction (inhibition of compensation reactions that could facilitate the onset of hypoglycaemic coma).</p><p>Avoid taking this medicine with insulin.</p><p><strong>+ Medicines that could cause a withdrawal reaction</strong></p><p>Withdrawal effect (hot flushes, redness, vomiting, tachycardia).</p><p>Avoid taking medicines that cause a withdrawal effect with this medicine, which contains alcohol. Consider the complete elimination of medicines by referring to their half-life before consuming alcoholic beverages or this medicine again.</p><p><strong>+&nbsp;&nbsp;&nbsp; Sedatives</strong></p><p>The fact that numerous medicines or substances may add their central nervous system depressant effects and contribute to a decrease in vigilance must be considered. These are morphine derivatives (analgesics, cough suppressants and replacement treatments), neuroleptics, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines (for example, meprobamate), hypnotics, sedative antidepressants (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine), sedative H1 antihistamines, central antihypertensives, baclofen and thalidomide.</p><p>The sedative effect of these substances is increased by alcohol. The alteration of vigilance may make driving and using machines dangerous.</p><p>Avoid taking this medicine with sedatives.</p><p><strong>+ Metformin</strong></p><p>Increased risk of lactic acidosis during acute alcohol intoxication, particularly in the case of fasting or denutrition, or even hepatocellular insufficiency.</p><p>Avoid taking this medicine with metformin.</p><p><strong>+&nbsp;&nbsp;&nbsp; Sulphamides&nbsp;&nbsp;&nbsp; hypoglycaemic&nbsp;&nbsp;&nbsp; agents&nbsp;&nbsp;&nbsp; (carbetamide,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chlorpropamide,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glibenclamide, gluconuride, gliclazide, glimepiride, glipizide, tolbutamide)</strong></p><p>Withdrawal effect, notably for glibenclamide, glipizide, tolbutamide. Increased hypoglycaemic reaction (inhibition of compensation reactions) that could facilitate the onset of hypoglycaemic coma.</p><p>Avoid taking this medicine with hypoglycaemic agents.</p><p><strong><u>Combinations to be considered</u></strong></p><p>+&nbsp;&nbsp; <strong>Nicotinic acid</strong></p><p>Risk of pruritus, redness and hot flushes, related to the potentiation of the vasodilator effect.</p><p><strong>+&nbsp;&nbsp; Vitamin K antagonist (acenocumarol, fluindione, phenindione, warfarin)</strong></p><p>Possible changes in the anticoagulant effect, with an increase in the event of acute intoxication or a decrease in the event of chronic alcoholism (increased metabolism).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Pregnancy</u></em></strong></p><p>Inhibition of prostaglandin synthesis by NSAIDs may affect the course of pregnancy and/or the development of the embryo or foetus.</p><p><u>Risks related to the use during the 1st trimester</u></p><p>Data of epidemiological studies suggests an increase in the risk of miscarriage, heart malformations and gastroschisis, after treatment by a prostaglandin synthesis inhibitor at the start of pregnancy. The absolute risk of cardiovascular malformations went from less than 1% in general population to approximately 1.5% in people exposed to NSAIDs. The risk appears to increase with dose and treatment duration. In animals, it has been shown that the administration of a prostaglandin synthesis inhibitor causes an increased risk of pre- and post-implant loss and a rise in embryo-foetal fatality. Moreover, a higher incidence of certain malformations, including cardiovascular malformations, has been reported in animals who received a prostaglandin synthesis inhibitor during the organogenesis phase of gestation.</p><p><u>Risks related to the use from the 12th week of amenorrhoea and until birth:</u></p><p>From the 12th week of amenorrhoea and until birth, all NSAIDs, by inhibition of prostaglandin synthesis, may expose the foetus to<strong> renal function disorder:</strong></p><p>o in utero observed from 12 weeks of amenorrhoea (start of foetal diuresis): oligoamnios (may occur shortly after starting treatment and is generally reversible after discontinuation of treatment), or anamnios, especially after extended exposure.</p><p>o at birth, renal impairment (reversible or irreversible) can persist, particularly in case of late and prolonged exposure (with a risk of severe delayed hyperkalaemia). The constriction of the arterial canal may occur during the second trimester (usually reversible upon discontinuation of the treatment).</p><p><u>Risks related to the use from the 24th week of amenorrhoea and until birth:</u></p><p>From the 24th week of amenorrhea, NSAIDs may expose the foetus to <strong>cardiopulmonary toxicity</strong> (premature closure of the ductus arteriosus and pulmonary arterial hypertension) and lead to foetal or neonatal right heart failure or foetal death in utero. This risk is greater the closer administration is to delivery (less reversibility). This effect occurs even with occasional administration.</p><p><u>At the end of pregnancy, the mother and newborn may have:</u></p><p>- increased bleeding time due to an anti-aggregating action, which may arise even after the administration of very small doses of the medicinal product;</p><p>- an inhibition of uterine contractions, resulting in a delay in term or prolonged delivery.</p><p><u>Consequently:</u></p><p>Unless absolutely necessary, this medicinal product must not be prescribed in a woman considering pregnancy or during the first 5 months of pregnancy (first 24 weeks of amenorrhoea). If this medicinal product is administered to a woman intending to get pregnant or who is less than 6 months pregnant, the dose should be as low as possible and the duration of treatment as short as possible. Prolonged use is highly inadvisable. The health care professionals should consider ultrasound monitoring of amniotic fluid if NSAID treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found.</p><p>Administration from the 20th week of amenorrhoea justifies cardiac and renal monitoring. In the event of oligoamnios, or constriction of the arterial canal, treatment with this medicine should be discontinued.</p><p>From the beginning of the 6th month (after 24 weeks of amenorrhoea): any ongoing administration, however brief, is contraindicated. An inadvertent use from this date requires cardiac and renal monitoring of the foetus or neonate, depending on the date of exposure. The duration of this monitoring depends on the elimination half-life of the molecule.</p><p>Benzyl alcohol may cross the placental barrier (see section 4.4)</p><p><strong>Breast-feeding</strong></p><p>Because NSAIDs pass into breast milk, this medicinal product is not recommended for use by breastfeeding women.</p><p><strong>Fertility</strong></p><p>Like all NSAIDs, the use of this medicinal product may temporary affect female fertility by acting on ovulation. It is therefore not recommended for women wishing to conceive a child. In women having difficulty conceiving or undergoing fertility tests, discontinuation of treatment should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients must be warned about the possible occurrence of dizziness and sleepiness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p>Gastro-intestinal effects are the most commonly encountered side effects. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, can occur, especially in the elderly (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, ulcerative stomatitis, abdominal pain, melena, hematemesis, exacerbation of ulcerative colitis or Crohn&#39;s disease (see section 4.4) have been reported following administration of NSAIDs. Less frequently, gastritis was observed.</p><p>Oedema, hypertension, and cardiac failure have been reported in association with NSAID treatment. The table below presents adverse drug reactions (ADRs) by system organ class (SOC) and frequency category. The ADRs are listed in order of decreasing medical seriousness within each frequency category and SOC.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be</strong></p><p><strong>estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;<strong>Blood and lymphatic system disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp; &nbsp;Aplastic anaemia* (Aplasia bone marrow)a Haemolytic&nbsp; &nbsp;anaemia* Eosinophilia* Leucopenia* Thromocytopenia*</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis* Serum sickness*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycaemia* Hypoglycaemia* Fluid retention* Sodium retention*</p><p>Hyperkalaemia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p><p>Somnolence</p><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Aseptic meningitis* Paresthesia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>Eye irritation* Swollen eyes*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hearing decreased*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasculitis* Hypertension*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm* Dyspnoea* Epistaxis*</p><p>Asthma crisis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Epigastric heaviness Nausea Constipation</p><p>Abdominal discomfort Flatulence</p><p>Abdominal pain Diarrhoea Vomiting</p><p>Indigestion</p></td><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>Perforation* Ulcers* Pancreatitis* Gastrointestinal bleeding (including hematemesis and melena)*</p><p>Gastritis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatal hepatitis* Severe hepatitis* Jaundice*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Skin rash Pruritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Edema Quincke&#39;s* (Angioedema*) Stevens-Johnson syndrome*</p><p>Toxic epidermal necrolysis (Lyell&#39;s disease)*</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)* Vesiculo bullous reactions*</p><p>Dermatitis exfoliative*</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge; 1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge; 1/1000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be</strong></p><p><strong>estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema multiforme* Photosensitisation* Fixed Drug Eruption* Non- thrombocytopenic purpura (Henoch- Schoenlein)* Onycholysis* Worsening of chronic urticaria*</p><p>Alopecia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Functional acute renal failure*</p><p>Nephrotic syndrome* Glomerulonephritis* Interstitial nephritis*</p><p>Papillary necrosis*</p><p>Acute tubular necrosis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Female fertility decreased*</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Oedema (mainly of lower extremities)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Local adverse reactions (burning sensations) or tissue damage (sterile abscess formation, fatty tissue necrosis) at the site of injection* Malaise*</p><p>Transient pain upon injection*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Reversible elevations of BUN</p><p>Transitory or reversible increased serum transaminase levels</p><p>Decreases in hemoglobin and hematocrit unassociated with obvious gastro-</p><p>intestinal bleeding</p></td><td style="vertical-align:top"><p>Reversible elevations of creatinine</p></td><td style="vertical-align:top"><p>Positive ANA* Transitory or reversible increased bilirubin*</p><p>Platelet aggregation decreased and Bleeding time increased*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a. Aplastic anemia is a form of bone marrow failure (aplasia bone marrow).</p><p>*ADR identified post-marketing.</p><p>ANA = antinuclear antibody; BUN = blood urea nitrogen.</p></td></tr></tbody></table><p><strong><u>Reporting of adverse reaction</u></strong></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t202"
  coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_16" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:110.5pt;margin-top:12.95pt;width:305.8pt;
  height:54.85pt;z-index:-15725568;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:5.15pt;line-height:12.55pt;
     mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'>National<span
     style='letter-spacing:-.4pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.4pt'> </span>Center<span style='letter-spacing:
     -.4pt'> </span><span style='letter-spacing:-.2pt'>(NPC)</span><o:p></o:p></b></p>
     <p class=MsoBodyText style='margin-left:5.15pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>SFDA<span style='letter-spacing:-.35pt'> </span>Call<span
     style='letter-spacing:-.1pt'> </span>center:<span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:127.9pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt'>E-mail: <a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue'>npc.drug@sfda.gov.sa</span></a><span
     style='color:blue'> </span>Website:<span style='letter-spacing:-.7pt'> </span><u
     style='text-underline:blue'><span style='color:blue'>https://ade.sfda.gov.sa/</span></u><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>SFDA Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: <u>https://ade.sfda.gov.sa/</u></p></td></tr></tbody></table><p><strong>Other GCC States</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_17" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:123.7pt;margin-top:18.4pt;width:304.95pt;height:13.2pt;z-index:-15725056;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAV2DsfjgDAAA/FAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWG1v2jAQ/j5p/8Hyd0p4f1FD1Ze1
mlS1CNofcDgOiebYmW1S2K/f2UlGxKROa7cvFBBg+47Hd8+dz7HPL7aZIAXXJlUypJ2zgBIumYpS
uQ7p89Nta0yJsSAjEErykO64oRezz5/OYbrWkCcpI4ggzRRCmlibT9ttwxKegTlTOZcoi5XOwGJX
r9uRhhdEzkS7GwTDdgappLM91A1YIBudvgFKKPaNR9cgCzAIKdi0OVLZKNj7kWEqizudL/O5dpaz
h2KuSRqFFJmTkCFFtF0JKjXstg/+td4DbGOdOX0Vx2SLERiMgskEsXYh7Qed3rg3KPH41hKGCr3x
qDseDihhqNEZjob9oJowefwDBEu+vA6CZpbmYKNhosmdgbL43efOqHb6Ce1bqS3Bkdp9p07s9ko5
t3yYTX6PYTIlIchcCejJqbFNxes/ouWXRzDNtbF3XGXENUKqObPeKCjujS1NqlWcu0KSl5AOg8mw
NF2JNLpNhXAyo9era6FJAQLj7l/Oa5zMNNUc3A2YpNTzokpNyFK7ctZul55iR1a0czOs8BfZw4Vp
H/ErFgqNYSLNKUmU/nE49oJLMaTm+wY0p0R8lcbno60bum6s6oa24lo56713Ul1urIrTiodyds+C
sUu7E9zH1NvogpqBvseYjoLOGDMVe4saSMhlzjxFOZtbU3re6Q59jiI/TfkVjw81azWTs730Mrav
6HkpIldUaqeq0UYBroJx2XpeYgX7geZ2gtJZHscY+zLoaBHYVBK7y3kMDFfvU5pxQx74C1moDCQl
OUhlUBB08T0MesEg6OOni60+SlPLklvIUuGWIxZLloA2HBOsWpYc/hs4eo2eOoftrOWyD3lyY56C
13kgyHBIu5OBD/9RMkL+khHcdcoqdZRszAUHw99CSZkqrc4RL55TqjRLCVPSArPvyJXuKVfqDYcc
d1mxybtqymn7+SB5orngBchTUdk/GjZL7mkDarLBVJZzy0/Z0jhINPl5U7Z8gMc42Fg8HKd2d3bw
7MJlNAcNiw9zLNw77E+EeHDH/NnfLmwMX+YLPASXlxbl9QNquIue9sHVmf9rddXn7uea/dlPAAAA
//8DAFBLAwQUAAYACAAAACEA4VE3H88GAADmGwAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1s7FnNb9xEFL8j8T+MfG+z381G3VTZzW4Dbdoo2Rb1OGvP2tOMPdbMbNK9ofaIhIQoiAOVuHFA
QKVW4lL+mkARFKn/Am9mbK8n65C0jaCC5pC1n3/zvt+br8tX7sUMHRAhKU96Xv1izUMk8XlAk7Dn
3RqPLqx6SCqcBJjxhPS8OZHelfX337uM13xG0wnHIhhHJCYIGCVyDfe8SKl0bWVF+kDG8iJPSQLf
plzEWMGrCFcCgQ9BQMxWGrVaZyXGNPHWgaPSjIYM/iVKaoLPxJ5mQ1CCY5B+czqlPjHYYL+uEXIu
B0ygA8x6HvAM+OGY3FMeYlgq+NDzaubPW1m/vILXskFMnTC2NG5k/rJx2YBgv2FkinBSCK2PWt1L
mwV/A2BqGTccDgfDesHPALDvg6VWlzLP1mi13s95lkD2cZn3oNautVx8iX9zSeduv99vdzNdLFMD
so+tJfxqrdPaaDh4A7L49hK+1d8YDDoO3oAsvrOEH13qdlou3oAiRpP9JbQO6GiUcS8gU862KuGr
AF+tZfAFCrKhyC4tYsoTdVKuxfguFyMAaCDDiiZIzVMyxT7k5ADHE0GxFoDXCC59sSRfLpG0LCR9
QVPV8z5MceKVIC+fff/y2RN0dP/p0f2fjh48OLr/o2XkjNrCSVge9eLbz/589DH648k3Lx5+UY2X
ZfyvP3zyy8+fVwOhfBbmPf/y8W9PHz//6tPfv3tYAd8QeFKGj2lMJLpBDtEuj8Ew4xVXczIRrzZi
HGFaHrGRhBInWEup4D9UkYO+Mccsi46jR5+4HrwtoH1UAa/O7joK70VipmiF5GtR7AC3OWd9Liq9
cE3LKrl5PEvCauFiVsbtYnxQJXuAEye+w1kKfTNPS8fwQUQcNXcYThQOSUIU0t/4PiEV1t2h1PHr
NvUFl3yq0B2K+phWumRMJ042LQZt0RjiMq+yGeLt+Gb7NupzVmX1JjlwkVAVmFUoPybMceNVPFM4
rmI5xjErO/w6VlGVkntz4ZdxQ6kg0iFhHA0DImXVmJsC7C0F/RqGjlUZ9m02j12kUHS/iud1zHkZ
ucn3BxGO0yrsHk2iMvYDuQ8pitEOV1Xwbe5WiH6HOODkxHDfpsQJ9+nd4BYNHZUWCaK/zISOJbRq
pwPHNPm7dswo9GObA+fXjqEBPv/6UUVmva2NeAPmpKpK2DrWfk/CHW+6Ay4C+vb33E08S3YIpPny
xPOu5b5rud5/vuWeVM9nbbSL3gptV68b7KLYLJHjE1fIU8rYnpozcl2aRbKEeSIYAVGPMztBUuyY
0gges77u4EKBzRgkuPqIqmgvwikssOueZhLKjHUoUcolbOwMuZK3xsMiXdltYVtvGGw/kFht88CS
m5qc7wsKNma2Cc3mMxfU1AzOKqx5KWMKZr+OsLpW6szS6kY10+ocaYXJEMNl04BYeBMWIAiWLeDl
DuzFtWjYmGBGAu13O/fmYTFROM8QyQgHJIuRtns5RnUTpDxXzEkA5E5FjPQm7xSvlaR1Nds3kHaW
IJXFtU4Ql0fvTaKUZ/AiSrpuj5UjS8rFyRJ02PO67UbbQz5Oe94U9rTwGKcQdanXfJiFcBrkK2HT
/tRiNlW+iGY3N8wtgjocU1i/Lxns9IFUSLWJZWRTw3zKUoAlWpLVv9EGt56XATbTX0OL5iokw7+m
BfjRDS2ZTomvysEuUbTv7GvWSvlMEbEXBYdowmZiF0P4daqCPQGVcDRhOoJ+gXM07W3zyW3OWdGV
T68MztIxSyOctVtdonklW7ip40IH81ZSD2yr1N0Y9+qmmJI/J1PKafw/M0XPJ3BS0Ax0BHw4lBUY
6XrteVyoiEMXSiPqjwQsHEzvgGyBs1j4DEkFJ8jmV5AD/WtrzvIwZQ0bPrVLQyQozEcqEoTsQFsy
2XcKs3o2d1mWLGNkMqqkrkyt2hNyQNhY98COnts9FEGqm26StQGDO55/7ntWQZNQL3LK9eb0kGLu
tTXwT698bDGDUW4fNgua3P+FihWzqh1vhudzb9kQ/WGxzGrlVQHCSlNBNyv711ThFada27GWLG60
c+UgissWA7FYEKVw3oP0P5j/qPCZvW3QE+qY70JvRXDRoJlB2kBWX7ALD6QbpCVOYOFkiTaZNCvr
2mzppL2WT9bnvNIt5B5zttbsLPF+RWcXizNXnFOL5+nszMOOry3tRFdDZI+XKJCm+UbGBKbq1mkb
p2gS1nse3PxAoO/BE9wdeUBraFpD0+AJLoRgsWRvcXpe9pBT4LulFJhmTmnmmFZOaeWUdk6BxVl2
X5JTOtCp9BUHXLHpHw/ltxmwgstuP/Km6lzNrf8FAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAA
ACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIw
EITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7ye
nOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGq
uzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9
/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABb
Q29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAA
AAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAFdg7H44AwAAPxQAAB8AAAAAAAAAAAAA
AAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEA4VE3
H88GAADmGwAAGgAAAAAAAAAAAAAAAACVBQAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwEC
LQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAACcDAAAY2xpcGJvYXJkL2RyYXdp
bmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAAJ8NAAAAAA==
" filled="f" strokeweight=".48pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:13.4pt;line-height:12.6pt;
     mso-line-height-rule:exactly'>-<span style='letter-spacing:2.95pt'> </span><i
     style='mso-bidi-font-style:normal'>Please<span style='letter-spacing:-.1pt'>
     </span>contact<span style='letter-spacing:-.2pt'> </span>the<span
     style='letter-spacing:-.15pt'> </span>relevant<span style='letter-spacing:
     -.2pt'> </span>competent<span style='letter-spacing:-.2pt'> </span><span
     style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Immediate transfer to a hospital.<br />&bull; Symptomatic treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: NON-STEROIDAL ANTI-INFLAMMATORY DRUG, ATC code: M01AC01</strong></p><p>Piroxicam is a non-steroidal anti-inflammatory agent of the oxicam group. It has the following actions:</p><p>&bull; analgesic action,</p><p>&bull; antipyretic action,</p><p>&bull; anti-inflammatory action,</p><p>&bull; inhibiting action on platelet aggregation.</p><p>These whole actions are linked to the inhibition of the prostaglandin synthesis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Piroxicam pharmacokinetic is linear. Various studies showed no pharmacokinetics difference according to the age.</p><p>&nbsp;</p><p><strong><u>Absorption</u></strong></p><p>A comparative study of the bioavailability of the injectable form with the oral form has shown:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After intramuscular administration of piroxicam plasma levels are significantly higher than those obtained after ingestion of capsules during the 45 minutes following the administration the first day and during thirty minutes the second day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A bioequivalence between the two forms.</p><p>&nbsp;</p><p><strong><u>Distribution</u></strong></p><p>Plasma elimination half-life: about 50 hours. After intramuscular injection of 40 mg of piroxicam, a Cmax of 3.80 &micro;g/mL is reached in 45 minutes (Tmax). Binding to plasma protein is high: about 99 per cent. Piroxicam rapidly crosses the synovial membrane: synovial levels are on average, 45 to 50% of blood levels. Binding to synovial fluid protein is the same as that seen in the plasma. A preliminary study showed that piroxicam is present in maternal milk (about 1 to 3% of plasma levels).</p><p>&nbsp;</p><p><strong><u>Biotransformation - Elimination</u></strong></p><p>The piroxicam is slowly eliminated. It is almost totally metabolised. Less than 5% of the ingested dose is eliminated unchanged in the urine and faeces. Piroxicam metabolism is predominantly mediated via cytochrome P450 CYP 2C9 in the liver. One of the main metabolic way is the hydroxylation of the pyridine nucleus of the lateral chain followed by a glucuronide conjugation and urinary elimination. Serum levels verified a year after continuous oral administration of 20 mg per day are the same as those when the initial state of equilibrium is reached. A study evaluated the pharmacokinetics of piroxicam administered at a single dose of 20 mg to healthy volunteers with genotype CYP2C9 *1/*1, CYP2C9 *1/*2 or CYP2C9 *1/*3. During the latter, it was observed for subjects with genotype CYP2C9 *1/*2 or CYP2C9 *1/*3, an increase of ASC0-&infin; and a&nbsp;decrease in oral clearance of piroxicam. It was also observed an increase in the inhibition of cyclooxygenase I by piroxicam for these patients. Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates should be administered piroxicam with caution as they may have abnormally high plasma levels due to reduced metabolic clearance (see section 4.4).</p><p><strong><u>Pharmacogenetics</u></strong></p><p>The activity of CYP2C9 is reduced in people presenting with genetic polymorphisms, such as CYP2C9*2 and CYP2C9*3 polymorphism. Limited data from two published reports show that subjects presenting with heterozygous genotypes CYP2C9*1/*2 (n = 9), heterozygotes CYP2C9*1/*3 (n = 9) and homozygotes CYP2C9*3/*3 (n = 1) had, respectively, systemic levels of piroxicam 1.7, 1.7 and 5.3 times greater than in subjects with a genotype CYP2C9*1/*1 (n = 17, metaboliser genotype) following the administration of a single dose via the oral route. The mean half-life elimination values of piroxicam in subjects presenting with CYP2C9*1/*3 (n = 9) and CYP2C9*3/*3 (n = 1) genotypes were, respectively, 1.7 and 8.8 times greater than those in subjects presenting with a CYP2C9*1/*1 (n = 17) genotype. We estimate that the frequency of the homozygote genotype *3/*3 ranges from 0% to 5.7% in different ethnic groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium dihydrogen phosphate dihydrate, nicotinamide, propylene glycol ethanol, benzyl alcohol, sodium hydroxide, concentrate hydrochloric acid, water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this drug should not be mixed with other drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
Do not use Feldene after the expiry date which is stated on the carton after EXP:. The expiry date 
refers to the last day of that month.
After opening: the product must be used immediately.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25C. Store away from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 mL in Ampoule: boxes of 5 ampoules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmacaeutical Plant, Saudi Arabia

MANUFACTURED BY:
SPIMACO, Al-Qassim Pharmacaeutical Plant, Saudi Arabia
Under license from: Pfizer Inc, New York, U.S.A

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>